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ABSTRACT 
The overall objective of the dissertation research was to determine if naturally 
occurring proteins/peptides, following oral ingestion, elicit antimicrobial activity in vivo. An 
initial study was designed to validate the sensitivity and precision of an in vitro antimicrobial 
assay, to evaluate the efficacy of natural animal proteins/peptides to kill in vitro antibiotic-
resistant and -susceptible bacteria, and to measure the effects of key components of animal 
digesta on the antimicrobial activity of these proteins/peptides. A radial diffusion assay using 
a lawn of a known bacteria grown in low electroendosmosis agar with the tested peptide 
placed into wells within the agar was utilized. Using the antimicrobial assay, the minimum 
inhibitory concentrations (MICs) of polymyxin B (control antibiotic) for Escherichia coli, 
Escherichia coli (nalidixic acid-resistant), and Staphylococcus aureus were 0.76, 0.76, and 
0.90 (ig/mL. respectively. The intra- and inter-assay variations for MIC determination were 
0.18 fig/mL and 0.2 |ig/mL. respectively. The natural animal proteins and peptides 
(lactoferrin, lactoferricin B, hen egg lysozyme, and alpha-lactalbumin LDT2) were assessed 
in vitro (acetic acid medium) for their ability to kill selected bacteria. Each of the tested 
proteins/peptides was active against a nalidixic acid-resistant strain of E. coli; however, the 
required concentrations for antimicrobial activity were 10 to 15 times higher than that of the 
non-isogenic. nalidixic-acid-susceptible strain. The antimicrobial activity of each 
protein/peptide in animal digesta fluid was 130 to 300 % greater than that in the acetic acid 
buffer. Lactoferrin activity was decreased (P<.07) when exposed to zinc, iron, magnesium, 
calcium, sodium, or potassium compared to the nontreated control. The antimicrobial activity 
of lysozyme was increased (P<.09) in the presence of zinc, magnesium, or calcium. The 
change in digesta pH from 6.5 to 2.4 resulted in a loss of antimicrobial activity of 65% for 
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lactoferrin. lactoferricin, and lysozyme. Therefore, the enhanced antimicrobial activity of the 
proteins/peptides in the presence of the digesta fluid is not due to the difference in pH or 
mineral concentration of the digesta. 
A second study was performed to evaluate the efficacy of orally ingested natural 
proteins/peptides in digesta to kill antibiotic-susceptible and -resistant bacteria, in vitro. The 
seven treatments consisted of a basal diet supplemented with no antimicrobial agent 
(control), or one of five natural proteins/peptides (lactoferrin. lactoferricin, lysozyme, 
neutrophil peptides or purothionin) or an antibiotic (polymyxin B). Weanling Sprague-
Dawley rats (35 ± 4 g) were self-fed the basal diet for a 6-day adjustment period and then 
their respective experimental diets for 3 days. Each rat was killed and digesta fluids from the 
small and large intestine were collected. Following oral ingestion, the proteins/peptides 
exhibited the ability to kill antibiotic-susceptible and -resistant strains of two Gram-negative 
and two Gram-positive bacteria. The minimum inhibitory concentration (MIC) of each 
protein/peptide needed to kill bacteria was less for digesta from the small vs large intestine 
(P<.06). for Gram-negative vs Gram-positive bacteria (Pc. 11), and for antibiotic susceptible 
vs resistant strains of bacteria( Pc. 10). The antibiotic polymyxin B also effectively killed in 
vivo each bacterium evaluated except antibiotic-resistant Staphylococcus aureus, while the 
control diet exhibited no antimicrobial activity. Polymyxin B was required (Pc.08) in the 
lowest concentration in the diet to elicit bacterial killing compared to the proteins/peptides; 
however, neutrophil peptides and purothionin exhibited the broadest spectrum of 
antimicrobial activity. Based on these results, ingested natural proteins/peptides retain 
antimicrobial activity in monogastric animals throughout the gastrointestinal tract and 
effectively kill both antibiotic-susceptible and -resistant bacteria. 
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CHAPTER 1. GENERAL INTRODUCTION 
Upon discovery of the power of antibiotics, the world has continually utilized these 
drugs to improve both human and animal welfare. However, through prolonged use and 
misuse of these compounds in both humans and animals, many bacteria have developed 
unique cell characteristics that allow them to be resistant to antibiotics (FDA, 2001; Brooks 
et al., 1998). Because of the increase in the numbers of multiple antibiotic resistance bacteria 
present today, a demand for antibiotic alternatives has arisen (FDA, 2001; NIAID, 2001). 
The innate immune system has various components that aid in the removing of 
bacteria. One of the primary phagocytic cells involved is the neutrophil. Neutrophils and 
other phagocytic cells possess various mechanisms for destroying bacteria, which include the 
use of antimicrobial proteins/peptides (AMPs). In addition to neutrophilic AMPs, the body 
can produce proteins, that when cleaved by select digestive enzymes, become antimicrobial 
(Hancock, 1997). 
Animal by-products also contain AMPs. Two such by-products are eggs and milk. 
Eggs possess the AMP lysozyme while milk contains a protein called lactoferrin. Lactoferrin 
plays a large role in the transport of iron in the milk to the young calf. However, lactoferrin 
and a cleaved peptide of lactoferrin, lactoferricin, can also kill Gram-negative bacteria and 
fungus (Pellegrini et al.. 1999; Yamauchi et al., 1993). 
A variety of plants utilized for animal and human food consumption also contain 
AMPs. Garcia-Olmedo et al. ( 1989) reviewed the many different types of antimicrobial 
peptides present in plants such as com, wheat, barley, and potatoes. 
With the large variety of AMPs present in both animals and plants, there is a potential 
to identify one or a combination of these AMPs that could be fed as a broad-spectrum 
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antimicrobial. In vitro data suggests that through the use of digestive enzymes, many other 
typically non-antimicrobial proteins can be cleaved into AMPs. The currently identified 
AMPs also possess the potential to kill antibiotic-resistant organisms. 
In the following two experiments, the ability of naturally occurring animal and plant 
proteins and peptides to elicit antimicrobial activity in the entire system of monogastries 
animals following oral ingestion are evaluated. 
Thesis Organization 
The thesis is divided into a literature review, two papers, and a general summary. The 
following papers were prepared for appropriate submission to the Journal of Animal Science. 
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CHAPTER 2. LITERATURE REVIEW 
Need For Antibiotic Substitutes 
With the recent restrictions of antibiotic use in food producing animals (European 
Commission. 1998), concerns about antibiotic-resistant bacteria in both the animal and 
human population and the desire to reduce food borne pathogen levels have arisen. Previous 
reports have indicated concern over the use of antimicrobials in food animals may in fact be 
transmitted to human through food (Khatchatourians, 1998). In addition, an increasing need 
to develop effective, environmentally compatible antimicrobial treatments has created a 
demand for antibiotic alternatives in the animal health and the medical health industries. 
Animal Antimicrobial Peptides 
The production of antimicrobial peptides (AMPs) is regulated by the transcriptional 
control ofNFKB-lKBa in antimicrobial peptide producing cells (Barra et al., 1998). The 
NFKB transcription factor is controlled by a group of ankyrin proteins termed IKB. An LPS-
Toll-like receptor interaction possibly with the co-receptor CD 14 triggers a signal to 
phosphorylate IKB, which is then degraded by the ubiquitin-proteasome pathway (Baldwin, 
1996; Diamond et al.. 1996; Zhang and Ghosh, 2001). Once IKB is removed, NFKB is 
translocated into the nucleus of antimicrobial producing cells where it binds to the DNA 
motif and stimulates peptide production of p-defensins (Brey and Hultmark, 1997). 
Simmaco et al. ( 1998) demonstrated that by treating the skin of frogs with a glucocorticoid 
cream, de novo synthesis of the immunopeptides was blocked when prepro-peptide mRNAs 
disappeared while licBa was upregulated. Schreck et al. ( 1992) also demonstrated that 
antioxidants suppressed the activation of NFKB. Glucocorticoids can also suppress the 
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NFKB-[KB(X pathway (Barra et al., 1998). Hancock ( 1997) reported that compounds such as 
glutamate, ceramide. and insulin will stimulate NFicB-mediated transcription which would 
result in a production of immune cell components such as IL-2. IL-6, MHC I, and 
immunopeptides (Baeuerle and Baltimore, 1991). 
The stimulation of the phosphorylation of IKB by cytokines suggests that by reducing 
the precursors to these cytokines would reduce activation of the NFKB transcription factor. 
Since arachidonic acid is the primary precursor to produce prostaglandins and leukotrienes 
that are important for cytokine synthesis, compounds such as conjugated linoleic acid can 
reduce the availability of arachidonic acid available to the cells for prostaglandin production 
and thus could potentially decrease cytokine production and ultimately AMP production. 
Antimicrobial peptides are produced in the bone marrow during neutrophil 
generation. It is during neutrophil generation that antimicrobial peptides can be transported 
into azurophilic granules within the neutrophil to allow for additional protection against 
bacteria. Many AMPs are synthesized in prepro-forms. For example, within the neutrophil, 
certain AMPs. called cathelicidins, are located in azurophilic granules and undergo a 
proteolytic cleavage by elastase at the N-terminal motif (cathelin) joined to a variable C-
terminal during neutrophil activation. These AMPs are also produced in the small intestine 
by endogenous secretions (e.g. pancreatic cells) and by the invasion of local neutrophils 
during periods of inflammation. The AMPs released into the intestine are not active until 
elastase cleaves the pro peptide fraction. 
Antimicrobial peptides can also be found in the oral cavity, the respiratory tract, and 
the skin (Weinberg et al., 1998). Most of the peptides found in these areas are p-defensins. 
These defensins and other orally based antimicrobial peptides are important in protecting the 
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oral cavity from infections that can occur during food consumption. For example, cattle 
consuming forages can be exposed to pieces of metal that can cut the oral cavity. At the 
same time, the forages can contain bacteria from the environment that could become disease 
producing if they enter the animal. By the feedstuffs being bathed in the antimicrobial agents 
in the saliva, microbes are killed that could cause gastrointestinal or systemic illnesses. 
Another benefit to animal antimicrobial peptides is that these cationic AMPs do have 
minimum inhibitory concentrations against antibiotic-resistant organisms (1-8 fig/mL) that 
are comparable to some of the more potent antibiotics. Giacometti et al. ( 1998) documented 
this antimicrobial activity and the needed concentrations of certain cationic AMPs on various 
microorganisms to elicit such a response. In general, most activity occurs between the 
concentrations of 0.25 to 128 ^ig/mL. 
Currently, four groupings of cationic peptides have been identified: 
Cysteine-rich. amphiphilic (3-sheet peptides (defensins-1 helix and protegrins); 
Cysteine-disulfide ring peptides with and without amphiphilic tails (bactenecin); 
Amphiphilic a-helical peptides without cysteine (cecropins - 2 -helix molecule 
(PI)); and 
Linear peptides with one or two predominant amino acids (PR-39 - proline-rich 
peptides, indolicidin - tryptophan-rich peptides) (Martin et al., 1995). 
Antimicrobial peptides can kill bacteria through a variety of different mechanisms 
(e.g. channel forming, binding DNA). The predominant mechanism involves binding to LPS 
on the bacterial membrane (Hancock et al., 1995). The binding of the peptide to LPS causes 
a displacement of native divalent cations, which promote self-uptake through the outer 
membrane. Once the peptide is through the outer membrane, it electrostatically binds with 
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negative headgroups of the phospholipids on the inner membrane. At this location, many 
AMPs will gather and insert into the cytoplasmic membrane of the bacteria to form channels 
that causes the disruption of the membrane and ultimately cell death. In addition, once the 
channels collapse, some peptides appear to disassociate and interact with cytoplasmic 
polyanions (DNA) (Zhang et al., 1999). 
Cysteine-rich. amphiphilic fi-sheet peptides 
Defensins 
Defensins are a group of variable cationic, arginine-rich, non-glycosylated peptides 
29-34 amino acids long with 6 cysteines, which are produced in the bone marrow (Ganz et 
al., 1990). Defensins are created as preprodefensins, which are 94-95 amino acids and 
prevent cytotoxic activity from occurring in the phagocyte (Ganz et al., 1990). The 
preprodefensin is then cleaved during phagocyte stimulation. 
Some defensins are found in saliva and other secretions, as well as in neutrophils. 
The activity of defensins ranges from antimicrobial and antiviral to chemotactic and 
hormonal. The antimicrobial activity of defensins is due to their amphiphilic nature and they 
are thought to create pores in bacteria to create the microbicidal activity. Upon dimerization, 
the defensin cationic polar end is moved to the outer region of the structure. Upon contact 
with the lipid membrane of the bacteria, the cationic arginine group of the defensin and the 
negatively charged head of the target membrane join and then the hydrophobic face of the 
defensin may be pulled into the membrane by an electromotive force. Several additional 
defensin dimers then bind together to disrupt the membrane surface (Martin et al., 1995). 
Beside the antimicrobial activity, defensins have other biological functions. 
Defensins have been shown to stimulate epidermal growth (Murphy et al., 1993) and 
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epithelial cell volume regulation (MacLeod et al., 1991). Defensins have also been shown to 
upregulate the release of histamine by inducing the GTPase activity, which then stimulates G 
protein activation (Befus et al., 1999). This pathway is different than the induced histamine 
release after IgE-dependent antigen and calcium stimulation. Cationic peptides have also 
been associated with a block of NADPH oxidase (Tal et al., 1998). In addition, defensins 
possess a secondary form of antimicrobial activity. Panyutich et al. ( 1994) demonstrated that 
a defensin molecule would bind with C lq complement. This will in turn stimulate the 
complement system to act upon foreign antigens. 
Because not all defensins are constitutively produced, defensin gene expression can 
be manipulated. The genes encoding defensins are located on chromosome 8 in both the 
human and the mouse and are regulated by the defensin RNA content of the phagocyte, as 
well as, the def genes. MCP-1 and MCP-2, which are turned on by IL-1(3 and IFN-gamma 
(Sparkes et al.. 1989: Ganz et al., 1985). The production of defensins can be suppressed 
through the release of certain hormones, while other defensin concentrations increase upon 
the presence of foreign antigens. Tsuruta et al. ( 1999) demonstrated that the addition of G-
CSF inhibited the expression of defensin mRNA. Panyutich et al. (1997) discovered that al-
proteinase inhibitor and al-antichymotrypsin inhibited defensin cytotoxicity. A novel mouse 
gene, Defb2. has been identified to have similar characteristics to mouse and human beta-
defensins. However. Defb2 is not expressed in the airways of healthy mice, which 
demonstrates that not all beta-defensins are active all of the time. The expression of Defb2, 
however, is induced upon administration of LPS (Morrison et al., 1999). 
Currently, there are two subtypes of defensins: alpha and beta. Six human a-
defensins have been identified. Human neutrophil peptides 1,2,3,4 are produced by 
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neutrophils, and HD-5 and HD-6 are produced by the Paneth cells in the small intestinal 
crypts. These defensins have activity against Gram-positive and Gram-negative bacteria, 
yeast, filamentous fungi, enveloped viruses, and mycobacteria. The a-defensins are unique 
in their mode of killing in that they form voltage-gated pores in the phospholipid bilayers of 
the membrane. These defensins are produced at approximately 5019 mg/kg of body weight 
per day in human bone marrow. They are then stored in the prepro-peptide form in the 
neutrophil's "azurophil" granules. After the neutrophils phagocytize a foreign antigen, these 
peptides from the granules are transferred into the vacuole that contains the foreign antigen, 
which then bathes the pathogen in mi 1 ligram/milliliter concentrations of defensins (Lehrer 
and Ganz. 1996). 
Lehrer et al. ( 1988) demonstrated that HNP-l and HNP-2 killed C. albicans, but 
HNP-3 did not. C. albicans was protected against HNP-1 in the absence of oxygen or in the 
presence of mitochondrial respiratory inhibitors. However, these respiratory inhibitors or 
anaerobiosis did not protect C. albicans from NP-1, poly-L-arginine, poly-L-lysine, or 
mellitin. Neutrophil defensin activity was inhibited with either Mg2+ or Ca2+, but not altered 
by the addition of Fe:+. However, Fe2+ did inhibit the activity of NP-1, a rabbit defensin, and 
HNP-l, 2. and 3 (Lehrer et al., 1988). Misuno et al. (1992) demonstrated that TNF-alpha 
production by SAC or PMA activated monocytes was decreased in the presence of HNP-l. 
Not only do the a-defensins protect against bacteria, viruses, and fungi, but some also 
inhibit ATCH-induced steroidogenesis (Masera et al., 1995). Human neutrophil peptide 1 
and HNP-4 inhibit spontaneous and cytokine-induced natural killer cell activity and increase 
the sensitivity to cortisol-dependent inhibition. Human neutrophil peptide I and HNP-4 also 
reduce IFN-gamma and IL-6 production (Masera et al., 1995). 
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Porter et al. ( 1997) demonstrated that recombinant human defensin 5 (rHD-5), found 
in the intestinal tract of humans, possesses antimicrobial activity against L. monocytogenes, 
E. coli. C. albicans, and S. enterica serovar Typhimurium. However, when 150 mM of 
sodium chloride (NaCl) was added to the in vitro solution, rHD-5 activity was reduced to the 
point of only being active against L. monocytogenes indicating that minerals present in 
digesta may alter the antimicrobial activity. At a pH of 5.5 (similar to that of the small 
intestine). rHD-5 activity was lost against S. enterica serovar Typhimurium, but not L. 
monocytogenes. The addition of trypsin to standard biological media caused some cleavage 
of the rHD-5: however, its activity against S. enterica serovar Typhimurium, was unchanged. 
Another animal, the rat, produces defensins as well. Rat defensin 5 (RD-5) 
expression was increased by 10-fold compared to control cells immediately following the 
termination of hemorrhagic shock. Rat defensin 5 is an alpha-defensin isolated in rat small 
intestine. Condon et al. ( 1999) demonstrated through this study that enteric defensins are 
inducible after injury, which demonstrates the potential of the defensins to promote intestinal 
lumen health and the reduction of secondary bacterial infections. 
Other gastrointestinal peptides present in rodents include cryptdin 1 and 2. Cryptdin 
1 and 2 are two defensins that have been found in the murine Paneth cells. These cryptdins 
possess activity against E. coli and L. monocytogenes. The potency was greater than HNP-l, 
but lower than NP-1. which is a defensin found in rabbit neutrophils and alveolar 
macrophages (Eisenhauer et al., 1992). 
The other subclass of defensins is the P-defensins. Beta-defensins can have many 
different functions within an organism. They can aid in the protection against foreign 
antigens in blood, mucusal linings, and epitheleal cell layers. 
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Just like the a-defensins. there are multiple P-defensins which have various roles 
within the mammal. Human P-detensin I (HBD-1 ) has been shown to circulate in the blood, 
as well as in the urogenital tract. According to Valore et al. ( 1998), HBD-1 mRNA can be 
located in the epithelial layers of the loop of Henle, distal tubules, and collecting ducts of the 
kidney. Human P-detensin 1 mRNA was also found in the vagina, ectocervix, endocervix, 
uterus, and fallopian tubes of the reproductive tract. Valore et al. ( 1998) also noted that 
HBD-1 was found in voided urine at a level of 10-100 |ig/L. Human P-defensin 1 was found 
in the blood plasma bound to carrier macromolecules that release the peptide under acidic 
conditions. No storage sites were found for HBD-1 in either the renal or female reproductive 
tract, and low pH did not alter the activity of HBD-1. However, a high salt concentration did 
inhibit the activity of these peptides (Valore et al., 1998). Tikhonov et al. ( 1997) 
demonstrated that in humans with pyelonephritis, IL-8 increased to 477 pg/mL in the urine, 
and defensins rose from 15.7 ng/mL to 134 ng/mL. These results indicate that during 
infection, defensins rise to bring the environment close to aseptic as compared to normal 
conditions. 
Human p-defensin 2 (HBD-2) has been isolated from keratinocytes. Singh et al. 
( 1998) demonstrated that IL-1P stimulated expression of HBD-2, but not HBD-1 in the 
epithelia of the trachea; however, both were found in the bronchoalveolar lavage fluid of 
humans, which demonstrates that some p-defensins are inducible. In addition, HBD-2 is the 
first human defensin that is expressed following direct stimulation of epithelial cells by 
Pseudomonas aeruginosa or cytokines (TNF-a and IL-1P) (Schroder and Harder, 1999). 
The HBD-2 gene and protein are expressed in keratinocytes associated with lesions, and the 
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protein has specific activity against Gram-negative bacteria and Candida (Schroder and 
Harder. 1999). Upon further comparison between HBD-1 andHBD2, Mathews et al. (1999) 
demonstrated that levels of HBD-2 increased 16-fold during a LPS exposure and only 
increased 5-fold with the addition of IL-1 p; however, HBD-1 was not altered and was 
determined to be constitutive. In addition, HBD-1 and HBD-2 are expressed in the oral 
cavity and secreted into the saliva demonstrating that these two peptides have a wide range of 
protection with the body. 
A homologue of HBD-2 found in mice is called mouse beta-defensin 3 (MBD-3). 
MBD-3 was found at low levels in epithelial cells of intestine and lung during a healthy, 
normal state. However, upon infection with P. aeruginosa, MBD-3 was upregulated in the 
airway, small bowel, and liver. An antimicrobial response against P. aeruginosa and E. coli 
D31 was also produced: however, the antimicrobial activity was reduced when salt 
concentrations increased indicating, once again, that certain cations/anions can affect the 
antimicrobial nature of these peptides (Bals et al., 1999). 
Beta-defensins can play a role in mucosal defense. An example of their role is 
demonstrated by bovine tracheal antimicrobial peptide (TAP), which has been isolated in 
periluminal. columnar, respiratory, epithelial cells, but not in bovine basal epithelial cells, 
alveolar macrophages, or submucosal glands, and whose expression is induced upon the 
exposure to LPS (Lehrer and Ganz, 1996). 
Porcine epithelial p-defensin 1 (PBD-l) has been identified in the epithelial cells of 
the tongue. Porcine P-defensin 1 was found to be highly concentrated in the O.lmm-thick 
layer of cornilied filiform papillae, the superficial squamous cells of the buccal mucosa at 
concentrations of 20 to 100 (ig/mL, as well as in the airway and oral mucosal membranes 
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(Shi et al., 1999). Zhang et al. ( 1999) isolated and cloned a full-length cDNA of a porcine 
beta-defensin (pBD-1 ) and demonstrated that the gene is located on chromosome 15ql4-
q 15.1. Porcine p-defensin is a peptide that is expressed during inflammation and infection. 
Porcine P-defensin 1 was upregulated following the administration of LPS, IL-1 beta, TNF-
alpha. or a 2-day infection of Salmonella enterica serovar Typhimurium. The inducible 
expression demonstrates that this peptide may play a critical role in maintaining a steady 
state of microbiota on mucosal epithelium. 
Protegrins 
Another AMP that is similar to defensins is protegrin. Protegrins are 16 to 18 amino 
acids in length and have been demonstrated by Shi and Ganz ( 1998) to kill Gram-positive 
and negative bacteria plus chlamydia, mycobacteria, and viruses like HIV-1. 
Cysteine-disulfide ring peptides with and without amphiphilic tails 
Bactenecin 
Bactenecin is a 12 amino acid AMP, which is located in bovine neutrophils (Gallis et 
al., 1989-1990). Bactenecin is a cyclic dodecapeptide that loses activity against Gram-
negative bacteria when cleaved into a linear peptide or when 2 cysteines are replaced with 
serine (Wu and Hancock, 1999). The primary mechanism of antimicrobial activity of 
bactenecin is to dissipate the membrane potential of bacteria. 
Scocchi et al. ( 1992) demonstrated that bactenecin is produced in a prepro-form in the 
bone marrow by immature myeloid cells and then is stored in neutrophils in the pro-form. 
Neutral serine proteases in the azurophils (elastase, cathepsin G, and proteinase) are also 
located within the neutrophil and are believed responsible for activating bactenecin. 
According to Scocchi et al. ( 1992), elastase is the protease responsible for cleavage of the 
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prepro-form of bactenecin. The cleavage to the active form of bactenecin can be replicated 
in vitro by solubilizing neutrophils at a neutral pH with non-denaturing detergent, which 
unmasks granular proteases and allows the cleavage of bactenecin (Zanetti et al.. 1990). 
Cleaved bactenecin inhibits E. coli and S. aureus growth at levels of 2-8 (ig/mL (Gallis et al., 
1989-1990). In addition, bactenecin kills P. aeruginosa (.5-4 pg/mL), S. enterica serovar 
Typhimurium. (8 (ig/mL), and E. cloacae (25-200 gg/mL) (Gennaro et al., 1989). This 
finding demonstrates that specific conditions (e.g., presence of cleavage enzymes) are 
required for the activation of bactenecin. 
Amphiphilic a-lielical peptides without cysteine 
Cecropins 
Cecropins have been identified as one type of antimicrobial peptide. Cecopin PI has 
been shown to attack both inner and outer membranes of bacteria at once and work faster 
than another AMP. PR-39 (see below) (Boman et al., 1993). Gram-negative bacteria are 
more sensitive to cecropins than Gram-positive bacteria, which exhibit minimal response 
(Moore et al.. 1996). In mammalian cells, cecropins A and PI create an uncoupling of 
respiratory control and inhibition of protein import, and at a higher concentrations, (15 |iM), 
respiration was inhibited (Hugosson et al., 1994). In vitro, 2-3 |iM of cecropins inhibited 
cell-associated production of HIV-1 by suppressing gene expression (Wachinger et al., 
1998). 
Currently, there are many different identified cecropins from both insects and 
mammals. Cecropin-Pl is a peptide that has been isolated from pig tissue. Cecropin-Pl is 
found in endocrine-like cells in the duodenum and at the apex of intestinal villi, as well as the 
Langerhans islets (glucagon producing cells) in the pancreas of the pig (Lundberg et al., 
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1991). However. cecropin-P I was not found in the colon or lung indicating that cecropin-Pl 
has a specific role in gut health. 
Cecropins A and B from Cecropia moths have been shown to be transcribed within 2 
h after live bacteria injection. These cecropins reach a maximum level after 48 h and are 
continuously expressed for several days (Gudmundsson et al., 1991). The cecropin D gene 
was delayed to appear at 48-96 h and reached a maximum after 144 hrs. Furukawa et al. 
( 1999) demonstrated that various chitin oligomers (dimer to hexamer) activated the gene 
expression of the cecropin B, specifically in fat body and haemocytes in the silkworm. 
Bombyx mori. Cecropin gene expression can also be activated by the presence of bacterial 
lipopolysaccharide and peptidoglycan (Furukawa et al., 1999; Yamano et al., 1998). 
Yamano et al. ( 1998) demonstrated that the silkworm genes for cecropin A have 5' upstream 
regions that contain NF-kappa B and IL-6RE. In Drosophila, the activation of cecropin A1 
requires the binding of the GATA motif to the kappa B site (Kadalayil et al., 1997). 
Morishima et al. ( 1997) demonstrated that inhibitors of phospholipase A2, cyclooxygenase, 
or lipoxygenase inhibit the induction of cecropin genes both in vivo and in culture. Injected 
arachidonic acid induces the expression of cecropin genes, which supports the theory that 
eicosanoids mediate the expression of these genes. 
Linear peptides with one or two predominant amino acids 
Proline-rich peptides 
Proline-rich peptides are synthesized in the bone marrow as prepro-peptides. After 
transfering from the bone marrow into neutrophil granules, they are known as pro peptides. 
The proline-rich peptides are released as active peptides upon neutrophil degranulation, 
which classifies them as cathelicidins (Wu et al., 1999). 
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This immunopeptide works against mainly Gram-negative bacteria, reduces 
inflammation, inhibits phagocyte NADPH oxidase to decrease tissue damage, and has 
demonstrated chemoattractant capabilities at 0.01-0.5 |iM with maximal response at 0.5-2 
fiM in neutrophils (Huang et al., 1997). 
One example of this class of AMP is PR-39, a peptide located in pig neutrophils. In 
addition, current studies have demonstrated bactericidal activity of the peptide in pig 
intestine. Prior to 42 days of age of the pig, pig neutrophils did not express PR-39 mRNA, 
although the mRNA was expressed in the kidney, liver, thymus, spleen and mesenteric lymph 
nodes. However, by 4 weeks of age, the mRNA had disappeared from all tissues (Wu et al., 
1999). The finding that PR-39 had disappeared from animal tissue indicates that synthesis of 
the peptide is relocated as the immune system matures and that this peptide is not produced 
immediately after birth. In addition, Agerberth et al. ( 1991 ) demonstrated a wide spectrum 
of antimicrobial activity for PR-39. During a 5. enterica serovar Typhimurium, infection, 
there is a three-fold increase in serum peripheral blood neutrophil peptide PR-39 from 13.6 
ng/mL by 10-14 days postinfection, indicating that this peptide is in fact inducible and has 
the potential to be modified by the environment (Zhang et al., 1997). 
The PR-39 peptide, just like defensins. utilized multiple mechanisms in the killing of 
bacteria. The PR-39 peptide is involved in removal of Gram-negative bacteria in a non-pore-
forming manner, mainly through the termination of DNA and protein synthesis (Huang et al., 
1997; Boman et al.. 1993). The peptide, PR-39, is also active against Gram-positive bacteria. 
The mechanism of porcine PR-39 is that it binds to SH3-containing proteins upon entering 
the cell. This peptide, PR-39. will also bind to pl30Cas, which is actively involved in cell 
signaling (Chan and Gallo. 1998). Porcine PR-39 has also been shown to stop protein 
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synthesis and induce degradation of DNA synthesis protein (Boman et al, 1993). Shi et al. 
( 1996b) demonstrated in vitro that the presence of PR-39 inhibits NADPH oxidase activity 
by blocking the assembly of the enzyme through the interaction with p47phox Src 3 domains 
in the cytosol and inhibits interaction with cytochrome b558, p22phox. However, this inhibition 
of NADPH oxidase causes a decline in oxygen-dependent microbicidal activity of 
neutrophils to regulate production arid decrease tissue damage. Also, because PR-39 is 
involved in tissue repair, the inhibition of the superoxide O2" anion reduces the amount of 
tissue damage during inflammation. 
Other benefits of the production of PR-39 include the fact that, in vitro, PR-39 
induces syndecans 1 and 4. which are heparan sulfate chain-carrying core proteins and aid in 
wound healing (Li et al.. 1997). Porcine PR-39, at 0.5-2 gM, also induces directed migration 
of neutrophils in a Ca2+-dependent manner in vitro, which is beneficial in the removal of 
foreign antigens from the system. This concentration is slightly lower than the concentration 
needed for bactericidal activity (Huang et al., 1997). The peptide. PR-39, also positively 
influences cell motility and metastatic potential (Fujimoto and Kohgo, 1998). 
The PR-39 gene sequence was performed by Agerberth et al. ( 1991). The sequence is 
as follows: R-R-R-P-R-P-P-Y-L-P-R-P-R-P-P-F-F-P-P-R-L-P-P-R-I-P-P-G-F-P-P-R-F-P-P-
R-F-P-NH3. The 5' end of the gene family contains NF-KB, IL-6, granulocyte macrophage-
colony stimulating factor (GM-CSF), and NF-1 binding motifs (Zhao et al., 1995). 
A shortened form of PR-39, known as PR-26, has been shown to be equally potent 
against S. enterica serovar Cholerasuis, and 5. enterica serovar Typhimurium (Shi et al., 
1996a). The fact that there is no reduction in activity could be because that utilizing only the 
first 26 amino acids from the NH? terminus does not alter the cationic charge of the peptide 
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nor the structure. 
Indolicidin 
Indolicidin is a another type of linear peptide with a predominant amino acid. In this 
case, indolicidin is a tryptophan rich peptide that has been located in cytoplasmic granules of 
neutrophils. The sequence of the peptide is H-I-L-P-W-K-W-P-W-W-P-W-R-R-NH2 
(Selsted et al.. 1992). 
Indolicidin is considered bioactive against Gram-positive and Gram-negative bacteria 
and fungi. Indolicidin penetrates the membranes of the bacteria, but does not lyse them. 
Instead, indolicidin induces filamentation and inhibits DNA synthesis (Subbalakshmi and 
Sitaram, 1998). In vitro, a level of 10 |ig/mL was lethal for S. aureus and E. coli cultures. 
According to Robinson, Jr. et al. ( 1998), indolicidin is also antiviral against HIV-1 when 
added at a concentration of 333 |xg / mL of media. A 50% inhibitory dose was achieved at 
67 to 100 fig/mL. The activity is believed to occur on the envelope of the virus, as well as 
through destruction of the infected lymphoblastoid cells. Indolicidin also has hemolytic 
activity (Subbalakshmi et al., 1996). 
Milk Antimicrobial Peptides 
Currently, there are a wide variety of proteins that are found in feedstuffs that when 
degraded by digestive enzymes (e.g. pepsin), can elicit antimicrobial activity. Some of these 
compounds include: casein, alpha-lactalbumin, and lactoferrin. 
Casein 
Casein, after degradation by pepsin, can form two peptide fragments that elicit 
antimicrobial properties (Recio and Visser, 1999). These AMPs have been shown to kill 
bacteria (E. coli. Linnocua, B. cereus, M.flavus, and S. therniophilus) at concentrations of 8 
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- 99 jiM. One of the antimicrobial peptides derived from casein, casocidin-I, kills E. coli 
and S. carnosus in vitro at levels of .100 to 1.400 fig of casocidin-I / mL of media (Zucht et 
al., 1995). 
Alpha-lactalbumin peptides 
Alpha-lactalbumin. when degraded by gastric enzymes (pepsin, trypsin, or 
chymotrypsin) in vitro, has been shown to produce three AMP (Pellegrini et al., 1999). These 
AMPs were placed in culture with various bacteria (E. coli. B. bronchisepticci, K. 
pneumoniae. P. aeruginosa. S. marcescens, B. subtilis, M. luteus, S. aureus, S. epidermidis, 
S. lentus, and S. zooepideniicus). Pellegrini et al. (1999) found that the AMPs were more 
active against Gram-positive than Gram-negative organisms at AMP levels of 1 X 10"6 and 
5.5 X 10 * M. 
Alpha-lactalbumin has also been demonstrated to stimulate the production of IL-1(3 
(Wong et al., 1998). The stimulation of IL-1(3 would create an increase in chemotaxis of the 
neutrophils to that area. These neutrophils contain AMP produced from the animal, which 
would serve as a secondary source of AMPs for the host and could potentially provide 
greater protection against disease. Alpha-lactalbumin has also been shown to stimulate 
spleen cell proliferation and immunoglobulin production (Wong et al., 1998). This suggests 
the potential for a Th2 response, which would result in increased antibody production. 
Alpha-lactalbumin can also trigger mucosal repair after injury, which is valuable in 
preventing bacterial attachment, proliferation, and bacterial invasion into the blood stream, 
due to the increase in IL-1. which has been shown to increase angiogenesis and cell growth 
(Kobayashi et al., 1998; Podolsky, 1997). 
Lactoferrin / lactoferricin 
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Another protein, lactoferrin, has been shown to have activity on immune function, as 
well as have antimicrobial activity. Lactoferrin is a 689 to 691 amino acid protein and is 
found in products of exocrine glands in the digestive, respiratory, and reproductive systems, 
as well as in blood, tears, saliva, seminal fluid, and products of the mammary gland (Britigan 
et al.. 1994: Levay and Viljeon, 1995; Pierce et al., 1991). Lactoferrin has two homologous 
domains rich with disulfide bridges and 2 sub-domains which bind ferric ions with 
bicarbonate anions (Haridas et al., 1995; Moore et al., 1997). In fact, lactoferrin binds iron at 
260 times higher affinity than serum transferrin at an affinity constant of 1020 (Baker et al., 
1994). 
Lactoferrin suppresses IFN-gamma and lymphocyte proliferation, and yet, according 
to Miyauchi et al. ( 1998) stimulates neutrophil production at 50-250 gg/mL. In addition, 
lactoferrin has been shown to bind to E. coli LPS and prevent the binding to macrophages; 
thereby decreasing the release of proinflammatory cytokines (Lee et al., 1998). 
Lactoferrin attacks the outer membrane of Gram-negative bacteria by binding to 
lipoic acid in E. coli and to teichoic acid of the Gram-positive S. aureus causing membrane 
blisters via amphipathic binding (Vorland et al., 1999; Yamauchi et al., 1993). This blister 
formation against E. coli, S. enterica serovar Typhimurium, and S. montevideo occurred at 20 
|iM of lactoferrin and was dependent on Ca++, Mg% and Few concentrations in vitro 
(Yamauchi et al., 1993). Lactoferrin has been shown in vitro to also kill Helicobacter pylori 
at .5 mg lactoferrin/mL of solution and can also kill Clostridium perfringens, which is in part 
due to its iron-binding properties (Dial et al., 1998; Tomita et al., 1998). The killing activity 
on bacteria also occurred at the same concentration when lactoferrin was converted in vitro to 
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lactoferricin by digestion using pepsin, trypsin, or chymotrypsin (Yamauchi et a., 1993). 
Milk proteins, such as lactoferrin, can also survive passage through the digestive tract 
intact suggesting that certain AMPs have the ability to retain antimicrobial activity after 
ingestion. Kuwata et al. ( 1998a) also demonstrated that mice fed milk containing 40 mg 
lactoferrin/mL of solution had lactoferrin fragments containing the lactoferricin region 
detectable in quantities of pmol/g of feces. 
Kuwata et al. ( 1998b) demonstrated that the conversion from lactoferrin to 
lactoferricin did occur in vivo. This was demonstrated by feeding bovine lactoferrin to a 
human subject and then recovering the lactoferricin from the gastric contents. Lactoferricin 
was produced from lactoferrin at a level of 10 mg lactoferrin/mL of saline = 16.9 fig 
lactoferricin/mL of gut fluid (5.4 x 10 s mol/L) (Kuwata et al.. 1998b). Lactoferricin has 
been shown to kill Gram-negative and Gram-positive bacteria (E. coli, S. enteritidis, K. 
pneumoniae. P. vulgaris. Yersinia enterocolitica, P. aeruginosa. Campylobacter jejuni, S. 
aureus. Streptococcus mutans. Corynebacterium diphtheriae, L. monocytogenes, and C. 
perfringens) in vitro at levels between 0.3 |lM and 150 |lM of lactoferricin (Bellamy et al. 
1992b). Jones et al. (1994) demonstrated that lactoferricin inhibited Candida albicans and 
Proteus species, while Pseudomonas cepacia and Serratia species were resistant to 
lactoferricin. Dionysius and Milne ( 1997) demonstrated that lactoferricin also killed L. 
monocytogenes and E. coli at 2 gM without involving any of the iron-binding sites on 
lactoferrin. Bellamy et al. ( 1992a) demonstrated that lactoferricin was active against E. coli 
over the pH range of 5.5 to 7.5 which would suggest the peptide would be active in the small 
and large intestine of an animal. However, Bellamy et al. ( 1992a) also demonstrated that 
antimicrobial activity was reduced with the addition of Na+, K+, Mg2+, Ca2+. The loss of 
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activity could be problematic since the previously mentioned cations are found within the 
digestive system of the animal. 
Both lactoferrin and lactoferricin ( 11, 33, 100 |ig/mL of solution) have been shown to 
stimulate the production of [L-8 (Miyauchi et al., 1998). The stimulation of IL-8 should 
result in an increase in neutrophil migration, which would increase the amount of AMPs 
present in the area. Vorland et al. ( 1999) demonstrated that lactoferricin of bovine origin is 
more active against E. coli and S. aureus than lactoferricin of human, murine, or caprine 
origin. 
Egg peptides 
Chicken eggs have been a source of interest due to their unique properties of 
providing all of the necessary antibodies and other protective mechanisms to the embryonic 
chick. One of the AMPs that has been identified is lysozyme. Lysozyme, as both an intact 
and cleaved protein, elicits antimicrobial activity similar to cecropin, membrane disruption 
(Epand and Vogel. 1999). 
Egg white lysozyme (3.9-250.0 (ig/mL) is antimicrobial against Pasteurella, 
Micrococcus, and Pseiulomonas species (Kalfa and Brogden, 1999). Hughey and Johnson 
( 1987) demonstrated that L. monocytogenes and C. botulinum were susceptible to lysozyme, 
while 5. aureus. Campylobacter jejuni, E. coli, and S. enterica serovar Typhimurium, were 
resistant. Ibrahim ( 1998) demonstrated that by reducing the enzyme activity of lysozyme, 
antimicrobial activity against Gram-negative, not Gram-positive, bacteria increased in 
comparison to lysozyme with a completely active enzyme function. These findings 
demonstrate that denatured or enzyme-inactive lysozyme has a greater antimicrobial activity, 
which could be due to a change in protein structure that would allow a more negatively 
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charged portion of the enzyme to be available for binding to bacteria. 
Plant Antimicrobial Peptides 
Plants, just like animals, have developed a complex array of AMPs for protection. 
Only disulfide-bonded peptides have been identified in plants (Garcia-Olmedo et al., 1998). 
Currently, there are six different classifications of the plant AMP: thionins, defensins, lipid 
transfer proteins, hevein and knottin-like peptides, four-cysteine peptides, and twelve-
cysteine peptides. 
Thioinins 
Thionins are 45-47 amino acids long and can be classified into five types (I-V), type 
V lacks a C-terminal nonapeptide (Garcia-Olmeda et al., 1998). Type I contains 45 amino 
acid residues with 8 of those being within the disulfide loop. One example of a type i is a 
thionin isolated from wheat endosperm (Balls et al., 1942). Type II thionins have four 
disulfide bridges, similar to Type I; however, the charge is less basic and the disulfide loop 
will contain one or two additional amino acids. Type II thionins can be isolated from barley 
(Bohlmann and Apel., 1991 ). Type III thionins have three disulfide bridges and contain 
fewer basic amino acids. The Type III thionins, which can be isolated from mistletoe, are 
usually 46 residues in length and have 9 residues within the disulfide loop. The fourth type 
of thionins can be extracted from cabbage and have the same amino acid length and disulfide 
structure as type II thionins: however most of the amino acids are neutral. The fifth, and 
final thionin type, can be located in kernels of wheat and are missing the second and eighth 
cysteines of type I thionins and are neutral in charge (Castagnaro et al., 1995). 
Thionins (e.g., barley endosperm thionin) are synthesized as propeptides. Once the 
propeptide is produced, the N-terminal signal peptide and the C-terminal acidic protein are 
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removed from the thionin protein ( Hernandez-Lucas, 1986). A possible role of thionins 
within the plant might be redox regulation of enzymes due to their ability to form disulfide 
bridges with other proteins (Diaz et al., 1992). Pineiro et al. ( 1995) demonstrated that 
thionins inhibited (3-glucoronidase and neomycin phosphotransferase by forming disulfide-
linked adducts. Fernandez de Caleya et al. ( 1976) demonstrated that wheat endosperm 
thionins could kill Pseudomonas, Xanthomonas, Agrobacterium, Erwinia, and 
Corynebacterium. In addition, thionins could kill both fungi and bacteria at concentrations 
similar to plant tissue levels ( 10"3 to Ï0"6 M) (Molina, 1993). Thionins induce leakage of 
intracellular material from bacteria and yeast; however, this antimicrobial activity can be 
reduced upon exposure to calcium, zinc, or iron (Garcia-Olmedo et al., 1989). 
Plant defensins 
In general, plant defensins are 45 to 54 amino acids long and contain eight disulfide-
linked cysteines and can either be constituitively synthesized or induced (Broekaert et ai., 
1997). Upon germination, radish seeds produce approximately 1 |ig of defensins/seed to 
serve as a defense mechanism (Terras et al., 1995). In addition, a small number of plant 
defensins are produced as propeptides (Gu et al., 1992; Terras et al., 1995). 
Defensins isolated from cereal plants have the ability to inhibit a-amlyase (Broekaert 
et al.. 1997). These defensins have been grouped into four types based on their antimicrobial 
activity. Group I defensins consists of antimicrobial activity against Gram-positive bacteria 
and fungi, while group II are those active only against fungi and kill without distorting 
hyphal branching. Group III defensins are active against both Gram-positive and -negative 
bacteria, and group IV are active against both Gram-positive and -negative bacteria, as well 
as fungi (Osborn et al., 1995; De Samblanx et al., 1996; De Samblanx et al., 1997). 
24 
Lipid transfer proteins 
Plant lipid transfer proteins (LTP) are involved in lipid shuttling between the 
endoplasmic reticulum and organelle membranes (Kader, 1996). In addition, these 90-95 
amino acid polypeptides are involved in the defense systems of both mono- and 
dicotyledonous plants (Kader. 1996). In general, the LTPs have 8 disulfide-linked cysteines, 
and have been found to be more active than thionins against Clavibacter michiganensis 
(Garcia-Olmedo et al.. 1995: Kader, 1996). 
Hevein- and knottin-like peptides 
Hevein is found in the latex of rubber trees and is a 43-amino acid, cysteine-rich 
peptide (Broekaert et al., 1997). The hevein peptide, in general, consists of eight disulfide 
linkages and contains three p-sheet strands and an a-helix turn that links the second and third 
strands (Andersen et al., 1993). The knottin-like peptides are 36-37 amino acids long and 
have 6 disulfide-linked cysteines (Le-Nguyen et al., 1990). Both peptides inhibit Gram-
positive bacteria and fungi and are expressed only in the seeds (Broekaert et al., 1997; Koo et 
al., 1998). 
Four-cysteine antimicrobial peptides 
Currently, two families of four-cysteine AMPs exist: MBP-l and lb-AMPs. The 
MBP-1 peptides are located in maize and are 33-residues in length. They are active against 
Gram-positive and Gram-negative bacteria and fungi (Duvick et al., 1992). The lb-AMPs are 
found in Impatiens balsamina seeds. The lb-AMPs are active only against Gram-positive 
bacteria and fungi (Tailor et al.. 1997). 
Twelve-cysteine antimicrobial peptides 
Snakin-1 is a 63-residue long twelve-cysteine AMP and is located in potato tubers. 
The peptide is active against Gram-positive and Gram-negative bacteria and fungi. Snakin-1 
aggregates bacteria: however, it has been shown not to have activity on the bacterial lipid 
membrane (Segura et al.. 1999). 
Mechanism of Action of Antimicrobial Peptides 
One of the main targets for AMPs against Gram-negative bacteria is the outer membrane, 
which contains lipopolysaccharide (LPS). The lipid A portion of the LPS possesses a 
negative charge, which attracts the cationic AMPs (Epand and Vogel, 1999). In contrast, the 
Gram-positive bacteria do not have an outer membrane and therefore no LPS. The cationic 
AMPs must then bind to a peptidoglycan, which contains teichoic acid (Epand and Vogel, 
1999). Therefore, if the primary mechanism of action for a specific AMP is to bind to a 
negative charge structure and form dimers or oligomers, and the Gram-positive organism 
does not possess a large quantity of teichoic acid, the peptide may be required at greater 
concentrations to bind to the organism or may not be electrostatically attracted to the 
organism at all. rendering the AMP ineffective. In addition. Schroder ( 1999) discusses the 
fact that AMPs can kill bacteria by lysing membranes via voltage-dependent channel 
formation or liposomal lysis, inhibiting DNA synthesis, or by the uncoupling of respiration 
of the mitochondria. 
Bacteria can develop resistance to antibiotics using a variety of mechanisms (e.g. shifts in 
production of enzymes that destroy antibiotics, membrane permeability or charge, structural 
targets for the antibiotic (e.g.. change in DNA transcription proteins to become resistant to 
nalidixic acid), metabolic pathway, or enzyme function) (Brooks et al., 1998). For instance, 
Enterobacteria mutants have an altered outer membrane and are resistant to polymyxin B; 
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however, they are still susceptible to AMPs (Epand and Vogel, 1999). This is due to the fact 
that AMPs can be electrostatically drawn to the lipopolysaccharide portion of the Gram-
negative bacteria cell membrane. A.bacterium may change the nature of its membrane (e.g. 
charge or lipid composition) to avoid the affects of an antibiotic, but it could still be 
susceptible to the activity of the AMPs (Epand and Vogel, 1999). Due to the fact that the 
membrane surface may have been altered to provide antibiotic resistance, it may require a 
higher concentration of AMPs to elicit a similar effect seen with the antibiotic-susceptible 
bacteria. However, the mutation created against an antibiotic could also change the cell 
membrane structure to make it more susceptible to certain AMPs with antimicrobial activity 
different than that of the antibiotic the bacterium is resistant to. 
Toxicity of Antimicrobial Peptides 
Most antimicrobial peptides bind to bacteria via an amphipathic interaction; 
however, some AMPs can bind to other cells via a zwitterionic interaction. For example, 
human erythrocytes (representatives of mammalian cells) are composed of zwitterionic 
phophatidylcholine and sphingomyelin phospholipids, which creates a lower affinity to select 
AMPs (e.g.. ceeropins. magainins) compared to bacterial cells (Shai, 1999). The lower 
affinity of mammalian cells and AMPs reduces the incidence of toxicity. 
Bactenecin, which is an antimicrobial peptide produced by leukocytes, has been 
demonstrated to be toxic to neuronal and glial cells in both rats and humans (Radermacher et 
al., 1993). Additional leukocyte peptides, indolicidin and to a lesser degree, bactenecin, were 
shown to have cytotoxic effects against human and rat T lymphocytes (Schluesener et al., 
1993). However, even with this cytotoxic capability, the systemic activity of peptides is low, 
so these peptides do not elicit an immunosuppressive effect. 
It is important to note that cytotoxic effects of plant thionins in mammalian cells have 
been reported: however, when mice, guinea pigs, and rabbits were orally administered type I 
thionins, no adverse effects were reported (Carrasco et al., 1981). Plant defensins, on the 
other hand, have been reported to elicit no toxicity effects in either plants or animals 
(Broekaert et al.. 1997). 
Bacterial Resistance to Antimicrobial Peptides 
Due to the various mechanisms by which AMPs elicit their antimicrobial activity, it 
seems difficult for bacteria to develop resistance (Epand and Vogel, 1999). During the 
killing of a bacterium, a macrophage will phagocytose an organism into a phagosome. Once 
inside the phagosme. the pH declines to less than 5 and nutrients are removed from the 
environment, a lysosomal compartment will then bind to the phagosome and release AMPs 
along with other products such as nitric oxide. The entire digestion process can take 
approximately 15 to 20 minutes (Ernst et al., 1999). 
Bacteria can evade this process through a variety of different ways: 1) prevent 
phagoctyosis ( Yersinia spp.). 2) alter phagocytosis into phagosome (Salmonella spp.), 3) 
escape by lysing the vacuolar membrane (Listeria and Shigella spp.), 4) block fusion of 
phagocytosis and lysis (Legionella spp.), 5) block acidification (Mycobacterium 
tuberculosis), or 6) resist AMP (Salmonella spp.). 
Resistance to AMPs occurs through the PhoP/PhoQ gene regulation of bacteria (Ernst 
et al., 1999). PhoP binds to gene promoters to control over 40 genes, while PhoQ activates 
histidine kinase, which in turn phosphorylates the amino terminus of PhoP. This 
phosphorylation step could be stopped through the reduction of magnesium and/or calcium 
present in the environment. PhoP binding to promoters causes a change in the outer 
membrane proteins, nonspecific acid phosphorylation, a change in Mg2* transporters, and a 
modification of the lipid A fraction of LPS. An aminoarabinose (with the aid of UDP-
glucose dehydrogenase) is added to the lipid A fraction. This modification reduces the 
electrostatic potential of the cell membrane; thereby, reducing the binding of the AMP to the 
membrane and making the bacterium more resistant to AMP activity. In addition, a myristate 
can be replaced with a 2-hydroxymyristate to decrease host recognition of the foreign antigen 
(Ernst et al.. 1999). Guo et al. ( 1998) demonstrated that PhoP/PhoQ gene, pagP, causes the 
increase in acetylation of lipid A. 
Brucella spp. Have been reported to be resistant to certain peptides, such as cecropin 
PI, lactoferricin B. defensin NP-2, bactenecin, and active peptides from cationic protein 18 
(Martinez de Tejada et al.. 1995). This is due to a modification in the core lipid A portion of 
LPS on the Brucella. In addition, B. cepacia, Proteus spp.. and Serratia spp. are resistant to 
various cationic peptides. The latter two produce proteases that cleave some cationic 
peptides, while B. cepacia has an outer membrane that does not permit AMP uptake 
(Hancock and Scott. 2000). Pseudomonasfluorescens. Enterococcusfaecalis, and 
Bifidobacterium bifidum have been reported to be resistant to lactoferricin (Dionysius and 
Milne, 1997). 
Although some work has been performed in vivo, the efficacy and value of these 
antimicrobial peptides in vivo for an extended period of time has not been demonstrated. We 
hypothesize that the feeding of these proteins/peptides will result in the presence of sufficient 
antimicrobial peptides within the digesta fluid that the enteric pathogen load of the animal 
will be reduced and that the innate immune response and integritiy of the animal ingesting 
these proteins/peptides will be improved. 
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CHAPTER 3: EVALUATION OF THE ANTIMICROBIAL ACTIVITY 
OF NATURAL ANIMAL PROTEINS/PEPTIDES IN VITRO 
A paper to be submitted to the Journal of Animal Science 
Laura L. Greiner1, Tim S. Stahly1'2, and Thad Stanton3 
Abstract 
The objectives of this research were to validate the sensitivity and precision of an in vitro 
assay for evaluating the antimicrobial efficacy of potential antimicrobials, to evaluate the 
efficacy of natural animal proteins/peptides to kill in vitro antibiotic-resistant and -
susceptible bacteria, and to determine the effects of key components of animal digesta (e.g., 
pH and cations) on the antimicrobial activity of these proteins/peptides. A radial diffusion 
assay using a lawn of a known bacteria grown in low electroendosmosis agar with the tested 
peptide placed into wells within the agar was utilized. Based on the linear relationship of 
microbial killing (net zone diameter) to the log concentration of each 
protein/peptide/antibiotic, the minimum inhibitory concentration (MIC) of each peptide was 
estimated as the x-intercept of the semi-logarithm regression. The MICs for polymyxin B 
(control antibiotic) were determined to be 0.76,0.76, and 0.90 (ig/mL for Escherichia coli, 
Escherichia coli (nalidixic acid-resistant), and Staphylococcus aureus, respectively. The 
intra- and inter-assay variation for MIC determination was 0.18 |ig/mL and 0.2 |Xg/mL, 
respectively. Each of the natural animal proteins and peptides (lactoferrin, lactoferricin B, 
hen egg lysozyme, and alpha-lactalbumin LDT2) were verified in vitro (acetic acid medium) 
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"To whom correspondence should be addressed. 
3USDA/ARS/National Animal Disease Center, Dayton Road, Ames, IA 50010. 
42 
to kill nalidixic acid-resistant E. coli (£. coli - NalR). However, the required concentrations 
of the proteins/peptides to kill E. coli - NalR were 10 to 15 times higher than that needed to 
kill the non-isogenic. nalidixic-acid-susceptible strain. The proteins/peptides, with the 
exception of lactoferricin. did not kill Staphylococcus aureus. The antimicrobial activity of 
each protein/peptide in animal digesta fluid was 130 to 300% greater than that in the acetic 
acid media. The antimicrobial activity of lactoferrin was decreased (P<.07) in the presence 
of zinc, iron, magnesium, calcium, sodium, or potassium compared to the nontreated control. 
The antimicrobial activity of lysozyme was increased (P<_09) in the presence of zinc, 
magnesium, or calcium. The change in digesta pH from 6.5 to 2.4 resulted in a loss of 
antimicrobial activity of 65% for lactoferrin, lactoferricin, and lysozyme. Therefore, the 
enhanced antimicrobial activity of the proteins/peptides in the presence of the digesta fluid 
versus acetic acid seems not to be due to the difference in pH or mineral concentration of the 
digesta. Based on these data, natural proteins/peptides represent potential antibiotic 
alternatives for monogastric animals. 
KEYWORDS: Antimicrobial, Natural proteins, Antibiotic resistant 
Introduction 
Recently, a need has arisen to develop effective but environmentally compatible, 
antibiotic alternatives because of restrictions of antibiotic use in food-producing animals 
(European Commission, 1998). In addition, there is an increasing interest to minimize the 
prevalence of antibiotic-resistant bacteria in both animal and human populations and to 
reduce pathogen populations in animal-derived food products (Piddock, 1996; Van Den 
Bogaard, 1997: Khachatourians, 1998). 
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Recently, natural proteins, called antimicrobial peptides (AMPs), have been isolated from 
various animal tissues and by-products. These AMPs have been shown in vitro to exhibit 
antimicrobial activity in bacteria via cell membrane destruction or DNA replication 
inhibition. In addition, other animal-derived proteins can directly form AMP upon 
degradation by digestive enzymes, stimulate endogenous synthesis of AMPs by the animal, 
and induce immune responses favorable to bacterial removal (Kuwata et al., 1998b; 
Miyauchi et al., 1998). 
Proteins with these antimicrobial characteristics have been identified as components 
of milk (e.g., lactoferrin, lactoferricin, and alpha-lactalbumin), eggs (e.g., lysozyme), and 
animal tissues (e.g.. defensins). Some AMPs, like defensins. selectively bind to the outer 
lipid membrane of the bacterial cell and form blisters and pores, which eventually result in 
lysis of the cell and cellular death ( Yamauchi et al., 1993) and provides a potential 
mechanism for killing antibiotic-resistant organisms. Select AMPs also have the ability to 
stimulate the production of IL-ip (Wong et al., 1998), which increases chemotaxis of 
neutrophils (that contain AMPs) to the infected site. Kuwata et al. ( 1998a) also demonstrated 
that mice fed milk containing 40 mg lactoferrin/mL of solution had lactoferrin fragments 
containing the lactoferricin region in detectable quantities in the feces, which demonstrates 
that some of the AMPs have the potential to survive the gastrointestinal tract. 
Based on these in vitro data, it is hypothesized that the feeding of these natural AMPs or 
their precursor will be effective in killing antibiotic-resistant and -susceptible bacteria as well 
as result in the enteric production of additional antimicrobial peptides. 
The objectives of this research were to validate the sensitivity and precision of an in vitro 
assay for evaluating the antimicrobial efficacy of these proteins, to evaluate the ability of 
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natural animal proteins/peptides to kill antibiotic-resistant and -susceptible bacteria in vitro, 
and to determine the effects of components of animal digesta (e.g., pH and cations) on the 
antimicrobial activity of these proteins/peptides. 
Materials and Methods 
Antimicrobial activity assay 
At the initiation of the experiments, bacteria were transferred from the culture tube to a 
trypticase soy agar (TSA) plate via a sterile loop to allow for the growth of individual 
colonies. The plates were incubated for 24-48 hours at 37°C. After this period of incubation, 
a single colony was transferred to a culture tube containing trypticase soy broth (TSB) and 
allowed to grow overnight at 37°C. From this tube, 100 |lL were removed and added to a 
new TSB tube for use in the radial diffusion assay based on Lehreret al. (1991). The radial 
diffusion assay was tested for sensitivity and then was used to determine the antimicrobial 
efficacy of the compounds. 
Briefly, organisms in the midlogarithmic phase were used by inoculating the TSB with 
the growing bacteria, as described above, for an additional 3 h at 37°C. The bacteria were 
centrifuged for 10 min. at 5,000 g and then washed in cold 10 mM sodium phosphate buffer 
(NaPB, pH 7.4) and resuspended in cold NaPB to achieve an optical density (620 nm) of 5 X 
107 colony forming units (CFU)/mL. A volume containing 1 X 106 bacterial CPU was added 
to 10 mL of melted sterile agarose ( 10 mM NaPB, 3% w/v TSB, 1% w/v of low 
electroendosmosis-type (EEO) agarose, and .02% v/v Tween 20). After vortexing the 
bacteria with the agar, the agar was poured into a 100 X 15-mm sterile petri dish. 
A 3-mm-diameter gel punch (sterilized between plates to reduce surface contamination) 
was used to make 12 evenly spaced wells in solidified agar medium. Five |lL of the control 
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fluid (0.01 % acetic acid) or fluid (either acetic acid or digesta) containing 
proteins/peptides/antibiotic were added to each well. The plates were incubated for 3 h at 
37°C to allow for AMP diffusion from the wells and then overlaid with 10 mL of sterile agar 
(6% w/v TSB and 1% w/v low EEO agarose) to encourage bacteria growth. 
The use of acetic acid as the assay solvent is of importance because cationic peptides 
dissolve better in mildly acidic solutions (R. Lehrer, personal communication). In addition, 
some AMPs (e.g., defensins, protegrins) contain intramolecular disulfide bonds, which are 
more stable in acidic conditions and essential for their antimicrobial activity. Also, these 
peptides can form dimers and oligomers, which can be minimized in acidic conditions (R. 
Lehrer, personal communication; Epand and Vogel, 1999). 
After a 12-h incubation at 37°C, the diameter of the clear zone surrounding the wells was 
measured with a 10 X measuring magnifier that contained a metric scale scribe in . 1-mm 
increments. The "net zone diameter" was determined by subtracting the well diameter from 
the zone diameter (clearance zone). The net zone diameter was then multiplied by 10 to 
remove any decimals for ease in graphing, therefore, the net zone diameter was expressed in 
units (.1 mm = I U of antimicrobial clearance) as described by Lehrer (personal 
communication). Additional aspects of the procedure are listed in Appendix B. 
Bacteria 
Two antibiotic-susceptible bacteria, a Gram-negative (Escherichia coli, DH10B (E. coli 
- Nals)) and a Gram-positive (Staphylococcus aureus, ATCC # 29213) bacterium were used 
to evaluate the efficacy of activity of the selected proteins/peptides. In addition, a transgenic 
antibiotic-resistant strain of Escherichia coli - nalidixic acid resistant (£. coli - NalR ) was 
evaluated. The E. coli and 5. aureus were donated by the National Animal Disease Center 
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(Ames, LA). The non-isogenic strain of E. coli - NalR was donated by Karl Dawson of 
Alltech (Nicholasville, KY) and was developed as a tracer organism in pig studies. Prior to 
usage, the bacteria had been stored as stock cultures in an -80°C freezer. To maintain 
nalidixic-resistance of the E. coli strain in vitro, 8 |ig of nalidixic acid / mL of TSB was 
added to the TSB culture tubes during growth, and .2 |ig of nalidixic acid / mL of agarose 
was added to each 10-mL tube of low EEO agarose. 
Evaluation of the sensitivity and precision of the antimicrobial activity assay 
The antimicrobial activity of each protein/peptide and the control antibiotic was 
evaluated at five concentrations (Table I) in vitro. The lowest of the five concentrations that 
each protein/peptide and antibiotic were evaluated represented the lowest concentration 
reported in the literature to inhibit in vitro antimicrobial activity (Bellamy et al., 1992; 
Yamauchi et al., 1993; Kalfa and Brogden, 1999; Pellegrini et al., 1999). The four additional 
concentrations consisted of doubling each concentration to produce a 2-fold serial dilution. 
The minimum inhibitory concentration (MIC) was defined as the smallest amount of 
peptide that would be needed to provide a detectable clearance zone in the tested 
antimicrobial assay. The MIC for each protein/peptide in the present study was determined 
by regressing the net zone diameter (U of antimicrobial clearance) against the protein/peptide 
concentrations (|ig/mL of media). The x value (peptide concentration) is reported on a 
logarithmic axis. The MIC is estimated from the x-intercept. 
The MIC of each peptide/protein and antibiotic was determined in three replicated assays 
conducted on each day for four days. The intra-assay variation for MIC values was 
determined by calculating the MIC from the five-dilution standard for each replication of 
each compound for one day and determining the variation between each of the MIC values 
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for each compound. The inter-assay variation for MIC values was determined by calculating 
the MIC from the five-dilution standard for each replication of each compound for each day 
for four days and determining the amount of variation between each of the MIC values taken 
over the four-day period for each compound. 
Proteins/Peptides/Antibiotic 
Lactoferrin (>95% pure) was provided by DMV International Nutritionals (Fraser, NY). 
Lactoferricin B and the alpha-lactalbumin peptide, LDT2 (Pellegrini et ai., 1999), were 
synthesized by Biopeptide Co.. LLC (San Diego, CA) at >90% purity. Hen egg lysozyme 
(>95% purity) and polymyxin B sulfate (> 6,000 USB units/mg) were obtained from Sigma 
(St. Louis. MO). 
In order to determine if various factors in the digesta would alter antimicrobial activity of 
the tested compounds, the antimicrobial activity of each protein/peptide was evaluated under 
a variety of conditions (e.g.. change in pH and in mineral concentration and the presence of 
swine digesta) that would occur if orally ingested. In this test evaluating digesta and 
subsequent tests using digesta as the media, the concentrations of each 
protein/peptide/antibiotic tested were chosen based on the following: the lactoferrin was 
added at 3,000 |ig/mL to ensure adequate antimicrobial activity in the event that binding of 
digesta minerals occurred (e.g., calcium, magnesium) while the other protein/peptides were 
evaluated at the second highest dilution used for the acetic acid test (Bellamy et al., 1992). 
The MIC for each protein/peptide/antibiotic in swine digesta was determined and compared 
with that determined in 0.01 % acetic acid. 
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Animal digesta collection and recovery 
Digesta fluid from three 110-kg pigs was collected. Prior to slaughter, the pigs were self-
fed a fortified corn-soybean meal diet. No antimicrobials were administered (orally or 
injected) to the animals for a minimum of three weeks prior to slaughter. Pigs were removed 
from feed for 2 hours, killed by exsanguination, and processed according to commercial 
standards (e.g.. bled, scalded, dehaired, and eviscerated) at the Iowa State University Meat 
Lab. After evisceration (approximately 15 min. postmortem), the duodenum and jejunum 
section of the gastrointestinal tract were isolated, clamped, and removed. The entire digesta 
contents were then collected from the duodenum and jejunum of the pig by squeezing the 
contents out of the lumen and collecting the contents into u glass jar. The digesta contents 
from each of the three pigs were then placed on ice, and then pooled into one sample 
(approximately 25 min. postmortem of the last pig). The pooled digesta sample was 
centrifuged at 10,000 x g for 20 min. at 37°C. The supernatant was collected and then 
centrifuged again at 10,000 x g for 20 min. at 37°C. This procedure was repeated one 
additional time. The supernatant was then placed in a sterile syringe and filtered through a 
series of three (iStar LB sterile syringe filters (5, 0.45, and 0.2 |im, Costar, Cambridge, MA) 
and then placed into sterile polypropylene tubes (approximately 90 min. postmortem). The 
sample was placed on ice until used in the radial diffusion assay that day. 
For determination of the antimicrobial activity of the proteins/peptides/antibiotic in the 
digesta fluid, the proteins/peptides/antibiotic were added to the digesta contents within 10 
min. of pooling the digesta contents. The proteins/peptides/antibiotic were added to the 
digesta fluid immediately prior to the first centrifugation at concentrations 3,000, 50, 250, 
and 1,200 |ig/mL for lactoferrin, lactoferricin, lysozyme, and polymyxin B, respectively. To 
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ensure that the antimicrobial activity of the tested compounds was not diminished during 
centrifugation, the previous described concentration of each protein/peptide/antibiotic were 
added to the centrifuged supernatant after the third centrifugation (within 90 min. 
postmortem). In addition, the same concentration of each protein/peptide/antibiotic were 
added to the filtered supernatant (95 min. postmortem) to verify that the AMPs did not bind 
to the filter during the final step. The antimicrobial activity elicited by each compound when 
added at the various stages of processing of the digesta (compounds added prior to 
centrifugation and after centrifugation) was then compared with that observed when the test 
compounds were added directly to filtered digesta fluid to verify that antimicrobial loss 
during the digesta collection and processing procedure used was minimal. In addition, 
antimicrobial activity of each protein/peptide/antibiotic from the filtered digesta fluid was 
then compared to the acetic acid control to determine if the addition of digesta fluid would 
inhibit antimicrobial activity. 
Effects of components of animal digesta on antimicrobial activity of AMPs 
Cationic minerals. The effect of the concentrations of six cations (Zn+, Mg2+, Ca2+, Fe:+, 
Na2+, and K+) on the antimicrobial activity of three proteins/peptides (lactoferrin, 
lactoferricin, and lysozyme) on E. coli - Nals were evaluated. 
Sources of Zn+ (Zinc oxide, 100% pure), Mg2+ (Magnesium oxide, 100% pure), Fe2+ 
(Ferric oxide, 99.98% pure), and Ca2+ (Calcium carbonate, >97% pure) were obtained from 
Fisher Scientific, Fair Lawn. NJ, and individually added to 0.01% acetic acid (pH 4.4 before 
addition of the minerals) to achieve seven concentrations of each mineral (0, 1,2,3,4, 5, or 6 
mM). Sources of Na+ (sodium chloride, 100% pure) and K+ (potassium chloride, 100% pure) 
were obtained from Fisher Scientific, Fair Lawn, NJ, and individually added to achieve 
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concentrations of 0, 20,40, 60, 80, and 100 mM. No pH adjustment was made to the media 
after the addition of the cations. Each concentration of each mineral with each compound 
was tested in duplicate. 
pH. The effect of pH on the antimicrobial activity of three proteins/peptides (lactoferrin, 
lactoferricin, and lysozyme) on E. coli - Nals was evaluated. The antimicrobial activity of 
each protein/peptide was evaluated in acetic acid and animal digesta with initial pHs of 4.4 
and 6.5, respectively. The pHs of acetic acid and digesta media were lowered to 2 and 2.4, 
respectively, by the addition of 1 N hydrochloric acid (HCl). The pH was measured through 
the use of a pH meter (Orion ATI Perfect Log R Meter #370). In all studies conducted unless 
otherwise noted, the pH of the acetic acid media used to soiubilize the 
proteins/peptides/antibiotic was 4.4. 
Enzyme inhibition. The effects of protease enzyme inhibition in digesta fluid on the 
antimicrobial activity of three proteins/peptides (lactoferrin, lactoferricin, and lysozyme) on 
E. coli - Nals were evaluated. Pepstatin A (>90% pure, Sigma), an inhibitor of acid 
proteases (e.g.. pepsin, renin, cathepsin A) and leupeptin, an inhibitor of trypsin, were each 
added at 200 |ig/mL of digesta content samples (pH 6.5) within 10 minutes after the digesta 
contents were collected from the pigs. The MIC values from enzyme-inhibited digesta were 
compared to non-inhibited digesta for evaluation of the effect of enzymes on the 
antimicrobial activity of the tested compounds. 
Data analysis 
The amount of bacterial killing (net zone diameter) was linearly related to the log 
concentration of each test protein/peptide/antibiotic. Based on the semilog regression 
equation in which the net zone diameter (.1mm = I unit) of bacterial clearance was regressed 
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against the log concentration of a protein/peptide (gg/mL) in a specific media, the minimum 
inhibitory concentration (MIC) of each protein/peptide was estimated. The MIC was defined 
as the x-intercept of the semi-log regression for each protein/peptide for each bacterium 
evaluated. Data were reported as means plus/minus standard error of the mean. 
The effects of minerals on the antimicrobial activity (net zone diameters) were analyzed 
using the GLM procedure of SAS ( 1999-2000). The mineral data were analyzed as 
orthogonal contrasts to compare the responses elicited from the acetic acid control (OmM) to 
that of the responses of the proteins/peptides/antibiotics tested when exposed to the various 
mineral concentrations. In addition, the antimicrobial activity of each protein/peptide in the 
presence of each mineral was tested for linear and quadratic response to media mineral 
concentrations. The net zone diameter values from the pH, mineral, and digesta studies were 
reported as means plus/minus the standard error of the mean. 
Results and Discussion 
Antimicrobial activity assay sensitivity and variation 
The antibiotic polymyxin B was initially used to determine the sensitivity and 
precision of the antimicrobial activity assay. Polymyxin B has been identified to cause outer 
membrane disruption, which according to Epand and Vogel ( 1999), may be considered 
sufficient for bacterial killing. The MIC value for polymyxin B was determined for E. coli -
Nals to be 0.76 ±0.17 |ig/mL. The intra- and inter-assay variation for MIC determination 
was 0.18 |ig/mL and 0.2 |ig/mL, respectively. 
Overall, the intra-assay variation for the determined MIC values against E. coli - Nals for 
the lactoferrin, lactoferricin, and lysozyme were 8.7,0.21, and 2.6 gg/mL, respectively. The 
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inter-assay variation for the MIC values of lactoferrin, lactoferricin, and lysozyme were 10.4, 
0.70, and 2.3 jig/mL, respectively (Appendix C). 
Antimicrobial efficacy of proteins/peptides in vitro 
The proteins/peptides and the antibiotic, polymyxin B, each exhibited antimicrobial 
activity, while the acetic acid control did not exhibit antimicrobial activity based on the in 
vitro assay (Table 2). These data validate that these proteins/peptides are efficacious in 
killing selected bacteria, and that AMPs possess the ability to kill nalidixic-acid-resistant as 
well as antibiotic-susceptible bacteria. The AMPs called defensins have also been reported 
to have the ability to other antibiotic-resistant organisms such as methicillin-resistant 5. 
aureus, vancomycin-resistant Enterococci, and multiple-antibiotic-resistant Gram-negative 
bacteria. 
In general, the MIC values of the protein/peptide determined in the present study are 
lower than those previously reported in the literature (Ganz et al., 1990; Bellamy et al., 1992; 
Jones et al., 1994: Dionysius and Milne, 1997; Hancock, 1997; Porter et al., 1997; Wong et 
al., 1998; Pellegrini et al., 1999). Literature values for the MICs (|ig/mL of media) of each 
of these proteins/peptides determined in vitro against E. coli are: >3,000 lactoferrin, 8-500 
lactoferricin, no effect of LDT2, >200 lysozyme (Appendix B) and against 5. aureus are: no 
effect of lactoferrin. 3-18 jug lactoferricin, 1-25 |ig LDT2, no effect of lysozyme (Appendix 
B). The lower protein/peptide concentrations needed for antimicrobial activity reported in 
the current study could be due to a variety of factors including the strains of bacteria tested 
and the purity and structure of the proteins/peptides tested. 
In contrast to other reports (Pellegrini et al., 1999; Pihlanto-Leppala et al., 1999), no 
antimicrobial activity was elicited by LDT2 activity in the present study. Due to the fact that 
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the alpha-lactalbumin peptide LDT2 had no effect on E. coli- Nals, it was not evaluated in 
the subsequent digesta fluid studies. A possible explanation for these data is that the peptide 
has been reported to only work against Gram-positive bacteria (e.g., S. aureus, M. luteus) and 
a Gram-negative bacterium {K. pneumoniae; Pellegrini et al., 1999). Recent evidence has 
also indicated that the peptide, as well as its protein precursor, must be present in at least 
dimer formation. Because the peptide was synthesized and purified, it is most likely not in 
dimer formation (H. E. Swaisgood, personal communication). The antimicrobial activity of 
LDT2 against the E. coli - NalR organism could be due to a mutation on the bacterial 
membrane or that this particular strain of E. coli, is in fact susceptible to LDT2. 
The decrease in needed protein concentration to elicit the antimicrobial activity of 
lactoferrin against the tested bacteria compared to the published data could be associated 
with the characteristics of the protein. For instance, the isolation procedures used for 
lactoferrin can have an impact on activity due to differences in peptide configuration or 
presence of additional components, such as iron. For example, an increase in iron bound to 
the lactoferrin molecule has been shown to decrease the bacteriostatic properties that 
lactoferrin possess, but does not alter the bactericidal portion of the protein, which is present 
after exposure to pepsin (Bellamy et al., 1992). 
The E. coli - NalR required AMP concentrations 10 to 15 times higher than that of the E. 
coli - Nals. However, the two E. coli strains are not isogenic, which implies that the 
nalidixic acid-resistant strain has a different genetic makeup than the E. coli - Nals and has 
the potential to possess a different response to the proteins/peptides. The greater 
concentration of the proteins/peptides needed to kill the nalidixic acid-resistant strain could 
be directly related to nalidixic acid-resistance, but is more likely due to the intrinsic 
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properties of the bacterium (e.g., alteration of DNA transcription proteins that prevents AMP 
binding) (Blondelleet al., 1999; Epand and Vogel, 1999; Shai, 1999). 
The fact that not all of the peptides work on Gram-positive bacteria is indicative that 
AMPs have a variety of mechanisms for killing bacteria. One of the main targets for AMPs 
against Gram-negative bacteria is the outer membrane, which contains lipopolysaccharide 
(LPS). The lipid A portion of the LPS possesses a negative charge, which attracts the 
cationic AMPs (Epand and Vogel. 1999). In contrast, the Gram-positive bacteria do not have 
an outer membrane and therefore no LPS. The cationic AMPs must then bind to a 
peptidoglycan. which contains teichoic acid (Epand and Vogel. 1999). Therefore, if the 
primary mechanism of action for a specific AMP is to bind to a negative charge structure, 
and the Gram-positive organism does not possess a large quantity of teichoic acid, the 
peptide will be ineffective in killing the organism. 
According to Schroder ( 1999), AMPs can kill bacteria by lysing membranes via voltage-
dependent channel formation, liposomal lysis, or by inhibiting DNA synthesis. Bacteria can 
develop resistance to antibiotics using a variety of mechanisms (e.g., shift in the production 
of enzymes that destroy antibiotics, membrane permeability or charge, structural target for 
the antibiotic, metabolic pathway, or enzyme functionality; Brooks et al., 1998). For 
instance. Ente rohacteria mutants have a defective outer membrane and are resistant to 
polymyxin B: however, they are still susceptible to AMPs (Epand and Vogel, 1999). This is 
because AMPs can be electrostatically drawn to the lipopolysaccharide portion of the Gram-
negative bacteria cell membrane. A bacterium may change the nature of its membrane (e.g., 
charge or lipid composition) via random mutations, but it could still be susceptible to the 
activity of the AMPs if the total charge on the lipid A portion of the Gram-negative organism 
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or the teichoic acid on the Gram-positive organism remains negative (Epand and Vogel, 
1999). 
Effect of digesta collection process on retention of antimicrobial activity 
The addition of each protein/peptide at the three different steps in the digesta collection 
process demonstrated that no antimicrobial activity was lost through the binding of the AMPs 
to digesta components, through centrifugation, or during the filtering process. To verify that 
no loss of antimicrobial activity occurred during the processing of the digesta, the net zone 
diameter of each protein/peptide/antibiotic in the acetic acid media was compared to that of 
the diameters elicited by each protein/peptide/antibiotic when added to the digesta after the 
digesta was filtered (Table 3). These results indicate that the collection process used did not 
alter detectable antimicrobial activity. 
Effects of components in intestinal digesta on antimicrobial activity of proteins/peptides in 
vitro 
The antimicrobial activity of the proteins/peptides against E. coli - Nals in vitro when 
present at equal concentrations was greater in pig digesta (up to four times as great) than that 
observed in the acetic acid media (Table 4), while the antimicrobial activity of the antibiotic, 
polymyxin B, was reduced (Table 4). No antimicrobial activity was detected in digesta fluid 
alone. Since AMPs are produced and found in the intestine, the fact that no activity was 
detected could be because the assay was not sufficiently sensitive to detect minute 
concentrations of endogenous peptides or that the endogenous peptides were in the intestinal 
lumen mucus layer and thus, not present in the digesta fluid per se (Mahida et al., 1997). 
The greater antimicrobial activity of lactoferrin in digesta is hypothesized to be due in 
part to role of the digestive enzyme, pepsin, in cleaving the protein into a more active peptide 
(lactoferricin B; Dionysius and Milne, 1997). However, the antimicrobial activity of 
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lactoferricin. the active peptide form of lactoferrin resulting from enzymatic cleavage, also 
exhibited greater antimicrobial activity in the digesta in digesta versus the acetic acid media, 
which would indicate that there are additional factors within the digesta fluid (possibly other 
trace minerals) that enhance the antimicrobial activity of the proteins/peptides when present 
in the digesta fluid. 
Adding protease enzyme inhibitors, pepstatin A and leupeptin, in the digesta fluid did not 
affect protein/peptide antimicrobial activity compared with that of the untreated digesta fluid 
(Table 5). The activity of the enzyme inhibitors is not diminished at the pH of the digesta 
fluid (6.5) or at the temperature of 37° C (Sigma, personal communication), which would 
suggest that the protease inhibition were at least partially effective in the digesta. 
The effects of mineral (cation) concentrations on the antimicrobial activity of the 
proteins/peptides in acetic acid media against E. coli - Nals are represented in Table 6. The 
presence of added Zn\ Mg:+, Fe2+, Ca2+, Na+, or K+ reduced (P<.07) the antimicrobial 
activity of lactoferrin, but did not alter the activity of lactoferricin. The presence of Zn+, 
Mg2+. Fe2+, or Ca2+ increased the antimicrobial activity of lysozyme (P<.09). In addition, as 
the Zn+ concentration increased from 1 to 6 mM, the lactoferrin antimicrobial activity 
returned to a level similar to that of the acetic acid control. The antimicrobial activity of 
lactoferrin increased linearly (P<.05) as the concentrations of Zn+, Mg2+, Fe2+, or Ca2+ 
increased from 1 to 6 mM. In addition, lysozyme exhibited a linear increase (P<.05) in 
antimicrobial activity as the concentrations of Mg2+or Ca2+ increased. 
Typical total ion concentrations in the digesta from the small intestine of the pig are as 
follows: Zn+ .7 mM, Mg2+ 15.7 mM, Fe2+ 2.3 mM, Ca2+ 46.1 mM, NaCl 138 mM, KC1 30.4 
mM (Dintzis et al.. 1995). According to Dintzis et al. ( 1995), free ion concentrations in 
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digesta of the small intestine of the pig are as follows: Zn+ . 11 mM, Mg2+ 6.4 mM, Fe2+ .02 
mM, Ca2+ 5.2 mM, NaCl 116.8 mM, KC1 26.7 mM. The cationic mineral concentrations 
used in the experiment were based on the free ion concentrations projected to be present in 
the pig digesta mentioned in the previous statement. According to our results, the cationic 
levels present in the digesta of the pig may cause a slight decrease in antimicrobial activity of 
lactoferrin and an increase in antimicrobial activity in lysozyme. 
In this study, the addition of the different cations to lactoferrin largely resulted in lower 
antimicrobial activity: however, as the concentrations of these cations increased there was an 
increase in antimicrobial activity, although the level of activity never reached the control 
level. The reduction in activity would be expected based on Bellamy et al. (1992); however, 
the increase in activity as the concentration increased was not expected and cannot be 
explained. 
Other literature has indicated that cationic minerals (Na+, K+, Mg2+, or Ca2+) decrease 
antimicrobial activity of lactoferricin (Bellamy et al., 1992). The decrease in antimicrobial 
activity that Bellamy et al. ( 1992) discusses could be due to the fact that cationic and anionic 
proteins/peptides are drawn to the anionic/cationic charges, respectively, of certain minerals. 
However, in this study, the increase in antimicrobial activity cannot be easily explained. One 
possible hypothesis is that the cations tested are eliciting an antimicrobial effect against the 
bacteria. Shimoda et al. ( 1995) demonstrates this possibility with the bactericidal effect of 
adding salt in a similar manner as our study. In Shimoda et al. ( 1995), the addition of salt to 
the antimicrobial peptides creates an effect on the bacterial surface, rather than binding to the 
protein/peptide itself. 
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Upon exposing the peptides to a pH of 2 (similar to that of the stomach), the 
antimicrobial activity of the proteins/peptides was reduced by about 33% compared with that 
of the peptides exposed to pHs of 4.4 and 6.5 in acetic acid and digesta fluid, respectively 
(Table 7). Lowering of the pH should alter the charges on various amino acids, which would 
change the proteins/peptides ability to bind bacteria (Voet and Voet, 1995; Lee et al., 1997; 
Dathe and Wieprecht. 1999). 
Because the tested cationic minerals did not affect the antimicrobial activity of 
lactoferricin and decreased lactoferrin activity, this suggests that the increase in antimicrobial 
activity in the digesta was not associated with the mineral composition of the pig digesta. 
The increase in the antimicrobial activity of lysozyme when exposed to cationic minerals 
does partially explain the increase in lysozyme activity in digesta when compared to the 
acetic acid control. In addition, the fact that the lowering of digesta pH reduced 
antimicrobial activity and that digestive enzymes present in the digesta did not alter the 
antimicrobial activity of the tested proteins/peptides indicates that there are other unidentified 
factors within the digesta fluid that can contribute to the increase in antimicrobial activity of 
these proteins/peptides. 
In this study, the authors have demonstrated that the antimicrobial assay selected can 
produce repeatable results with low variation, although limited in sensitivity due to the size 
of the well needed to add in the test compounds. In addition, the selected antimicrobial 
proteins/peptides possess the ability to kill selected Gram-negative and Gram-positive 
organisms and do have the potential to kill nalidixic-acid resistant organisms. Finally, the 
authors have been able to provide information that indicates that these proteins/peptides have 
the ability to maintain antimicrobial activity in the presence of digestive enzymes, pH 
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changes, and varying concentrations of cationic mineral concentrations present in the 
animal's gastrointestinal system, which provides the evidence needed to support the 
hypothesis that these proteins/peptides could be fed to animals and elicit antimicrobial 
activity within the digestive system. 
Implications 
The antimicrobial radial diffusion assay has been shown to be a sensitive and precise 
assay for evaluated antimicrobial activity with low intra- and inter-assay variation. 
Furthermore, natural proteins/peptides from milk and eggs when added to either acetic acid 
or digesta fluid have been shown to elicit antimicrobial activity against antibiotic-susceptible 
and nalidixic acid-resistant bacteria and can maintain antimicrobial activity in the presence of 
various digesta components (e.g., pH, mineral composition). The MIC values received in 
these studies can be applied to developing AMP concentrations to be fed to animals as 
antibiotic substitutes. 
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Table 1. Concentration (fig/mL) of each protein/peptide/antibiotic used in the 
evaluation of the sensitivity and precision of the in vitro antimicrobial assay and to 
determine minimum inhibitory concentrations against nalidixic acid-susceptible 
Escherichia coli. 
Concentration 
Protein/Pegtide/Antib^^ 
Lactoferrin 3000 
1500 
750 
375 
188 
Lactoferricin 100 
50 
25 
12.5 
6.25 
Lysozyme 500 
250 
125 
62.5 
31.25 
Alpha-lactalbumin LDT2 100 
50 
25 
12.5 
6.25 
Polymyxin B 2400 
1200 
600 
300 
150 
•
l Values selected by using published minimum inhibitory concentrations as the lowest 
dilution in this series of 2-fold dilutions (Bellamy et al., 1992; Yamauchi et al., 1993; Kalfa 
and Brogden, 1999; Pelligrini et al., 1999). 
Table 2. Minimum inhibitory concentrations (MIC, pg/mL) of protein/peptide/antibiotic against selected bacteria 
determined in vitro in acetic acid media (pH 4.4)/ 
Bacteria Antibiotic Protein/Peptide 
Nalidixic Acid 
Bacteria Responsiveness Polymyxin B Lactoferrin Lactoferricin LDT2 Lysozyme 
Gram-negative 
Escherichia coli Susceptible .76 ±. 17 6.4 ± 1.2 2.15 ±.34 Und" 7.06 ± .68 
Escherichia coli Resistant ,76± .18 100 ± 13 20 ±2.2 250 ± 19 100± 15 
Gram-positive 
Und'' Staphylococcus aureus Susceptible .90 ± .20 Und1' 2.10 ±.34 Und" 
a The range of concentrations used to determine MIC values for each antibiotic and proteins/peptides are outlined in 
Table 1. The MIC was determined from the semi-logarithim regression of compound concentrations against the net zone 
exhibited for each bacteria evaluated. The values represent mean ± SEM determined from 12 replications of the MIC 
determination for each protein/peptide/antibiotic for each bacteria tested. 
h No antimicrobial activity detected at the highest peptide concentration evaluated. 
Table 3. Effect of digesta collection processing procedures on antimicrobial activity of protein/peptide/antibiotic 
against nalidixic acid-susceptible Escherichia coli. Values reported as net zone diameter expressed in units (.1 mm 
net zone diameter = I U).'1 
Protein/Peptide Added At Each Point in Digesta Collection Processing 
• a trivial/1 vpuuu 
Antibiotic (|ig/mL) Prior to Centrifugation After Centrifugation Before Filter After Filter 
Lactoferrin 3(MM) 101.41.6 110.1 ±.5 108.71.4 109.71.3 
Lactoferricin 50 69.0 ± .6 73.1 ± .8 70.5 1.7 71.01.6 
Lysozyme 250 80.1 ±.6 81.51.9 82.41 1.0 81.71.9 
Polymyxin B 12(H) 24.2 ± 1.0 24.81 1.5 23.91 1.2 24.01 1.3 
a Values represent the means ± SEM of three samples. 
Table 4. Effect of assay media on the antimicrobial activity of protein/peptide/antibiotic against nalidixic acid-susceptible m 
Escherichia coli. Values reported as net zone diameter expressed in units (.1 mm net zone diameter - 1 U)." 
Protein/Peptide/Antibiotic Assay Media 
Relative 
Antimicrobial 
Activityh Source 
Concentration 
(Hg/mL) Acetic Acid Digesta Fluid 
No Addition 010 010 0 
Lactoferrin 3000 25.010 109.7 1.3 439 
Lactoferricin 50 30.010 71.01.6 237 
Lysozyme 250 69.010 81.71.9 118 
Polymyxin B 1200 75.010 24.01 1.3 32 
u Values represent the means ± SEM of three samples. 
h Relative antimicrobial activity of each compound in the digesta fluid (pH 6.5) reported as a percentage of that observed 
in the acetic acid media (pH 4.4). 
Table 5. Effect of protease enzyme inhibitors on the antimicrobial activity of protein/peptide/antibiotic against 
nalidixic acid susceptible Escherichia coli in digesta. Values reported as net zone diameter expressed in units 
(.1 mm net zone diameter = 1 U). " 
Antibiotic/ 
Protein/Peptide (Hg/mL) 
Digesta Fluid 
Control Enzyme Inhibitorsh 
Lactoferrin 3000 109.7 ±.3 108.5 ±.7 
Lactoferricin 50 71.0 ±.6 71.5 ± .9 
Lysozyme 250 81.7 ±.9 79.9 ± .3 
Polymyxin B 1200 24.0 ± 1.3 23.5 ± 1.5 
a Values represent the means ± SEM of three samples. 
b Pepstatin A and leupeptin each added at 200 |ig/mL of digesta. 
Ox 
o> 
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Table 6. Effects of mineral concentrations on antimicrobial activity of proteins/peptides 
in vitro in acetic acid media against nalidixic acid-susceptible Escherichia coli. Values 
reported as mean net zone diameter expressed in units (.1 mm net zone diameter = 1 U) 
with standard error of the mean. 
Mineral in Media Protein/Peptides Concentration in Media (flg/mL)! 
Concentration 
(mM) 
Lactoferrin 
(3,000) 
Lactoferricin 
(50) 
Lysozyme 
None 
ZtT c-d'c 
2+ c.J.I 
Fe 2+ c.d.c.r 
Ca 2+ c.d.r 
0 
2 
3 
4 
5 
6 
1 
2 
3 
4 
5 
6 
2 
3 
4 
5 
6 
1 
2 
3 
4 
5 
6 
36.0 ±0.2 
14.0 ± 1.0 
20.0 ±0.0 
27.5 ±2.5 
29.0 ± 1.0 
33.5 ±2.5 
31.0 ± 1.0 
12.5 ±0.5 
20.5 ±0.5 
24.5 ±0.5 
33.5 ±5.5 
30.5 ±0.5 
31.0 ± 1.0 
5.0 ± 1.5 
5.0 ± 1.0 
15.5 ±0.5 
14.5 ±0.5 
12.0 ±0.0 
14.5 ± 1.5 
14.5 ±0.5 
15.0 ± 1.0 
15.5 ±0.5 
14.5 ±0.5 
15.0 ±0.0 
17.0 ± 1.0 
55.0 ± 1.9 
50.0 ± 0.0 
53.0 ±3.0 
53.0 ± 1.0 
51.0 ± 1.0 
51.0 ±0.0 
52.5 ± 0.5 
51.5 ±0.5 
54.0 ± 0.0 
53.0 ±0.0 
55.5 ± 0.5 
55.5 ±0.5 
53.0 ± 1.0 
55.5 ±0.5 
53.0 ± 1.0 
54.5 ±0.5 
56.0 ± 0.0 
56.5 ± 1.5 
56.5 ±0.5 
54.0 ± 0.0 
56.5 ± 1.5 
55.5 ±0.5 
53.0 ± 1.0 
56.0 ± 1.0 
55.5 ±0.5 
58.0 ±3.3 
65.0 ±0.0 
65.0 ±0.0 
60.0 ±5.0 
60.0 ±5.0 
57.0 ± 3.0 
58.5 ± 3.5 
51.0 ±4.0 
57.0 ± 7.0 
64.0 ± 0.0 
64.5 ±9.5 
70.5 ± 2.5 
66.5 ± 1.5 
64.5 ±0.5 
65.5 ±0.5 
64.0 ±0.0 
62.5 ±0.5 
62.5 ±0.5 
63.5 ±0.5 
57.5 ± 2.5 
55.0 ± 2.0 
62.5 ±2.5 
61.5 ±3.5 
65.0 ± 5.0 
66.0 ± 1.0 
68 
NaCl bjLc 
20 10.0 ±0.0 53.0 ± 1.0 62.5 ± 2.5 
40 8.5 ± 1.5 54.5 ±0.5 54.0 ± 1.0 
60 9.0 ± 0.0 52.5 ± 0.5 56.0 ± 1.0 
80 9.5 ± 0.5 55.5 ± 0.5 54.5 ± 0.5 
100 10.0 ±0.0 53.0 ± 1.0 56.5 ± 1.5 
20 12.0 ± 1.0 53.5 ± 1.0 54.0 ± 2.5 
40 9.0 ± 1.5 55.0 ±0.5 58.0 ± 1.5 
60 10.0 ± 1.0 54.0 ± 1.0 56.0 ± 1.0 
80 11.0 ±0.5 54.5 ± 1.5 55.5 ± 0.0 
100 9.5 ±0.0 55.0 ± 1.0 55.0 ± 0.5 
a Values are reported as means ± SD. The value for each concentration of each mineral is 
representative of 2 replications. 
h NaCl and KC1 levels for digesta are reported as Na and K ions, not the salt concentrations. 
c The presence of Zn\ Mg2+, Fe2+, or Ca2+ increased the antimicrobial activity of lysozyme 
(Pc.09). 
dThe presence of added Zn+, Mg2+, Fe2+, Ca2+, Na+, or K+ reduced (P<.07) the antimicrobial 
activity of lactoferrin 
0 Linear decrease (P<. 10) in antimicrobial activity when lysozyme was exposed to Zn ( 1 to 6 
mM) or Na (20 to 100 mM). 
r Linear increase (P<.05) in antimicrobial activity when lactoferrin was exposed to Zn, Mg, 
Fe, and Ca ( 1 to 6 mM): and lysozyme was exposed to Mg or Ca ( 1 to 6 mM). 
Table 7. Effect of media pH on antimicrobial activity of protein/peptide/antibiotic against nalidixic 
acid-susceptible Escherichia coli. Values reported as net zone diameter expressed in units (.1 mm net zone 
diameter = 1 U).a,b 
Acetic Acid Media Digesta Fluid Media 
Antibiotic/ % % 
Protein/Peptide (Hg/mL) pH 4.4 pH 2 ActivityL pH 6.5 pH 2.4 Activityc 
Lactoferrin 3000 25.0 ±0 17.7 ±2.7 71 109.7 ±.3 39.3 ± 2.3 36 
Lactoferricin 50 30.0 ± 0 15.0 ± 0 50 71.0 ± .6 32.3 ± .8 45 
Lysozyme 250 69.0 ± 0 60.3 ± .3 87 81.7 ±.9 71.0 ± 1.3 87 
Polymyxin B 1200 75.0 ±0 67.3 ± 1.3 90 24.0 ± 1.3 24.0 ± 0 100 
" Each value represent the mean ± SEM of three samples. 
h pH evaluated using a pH meter (Orion ATI Perfect Log R Meter #370). 
0 Relative antimicrobial activity of each compound in each medium reported as a percentage of that observed at the o\ 
higher media pH. ^ 
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CHAPTER 4: EFFICACY OF ANTIMICROBIAL PEPTIDE PRECURSORS AS AN 
ANTIBIOTIC ALTERNATIVE 
A paper to be submitted to the Journal of Animal Science 
Laura L. Greiner1, Tim S. Stahly1", and Thad Stanton3 
Abstract 
The objective of this research was to evaluate the efficacy of orally ingested natural 
proteins/peptides to kill enteric bacteria, including antibiotic-susceptible and -resistant 
strains, in vitro. The seven dietary treatments consisted of a basal diet supplemented with no 
antimicrobial agent (control), or one of five natural proteins/peptides (lactoferrin, 
lactoferricin, lysozyme, neutrophil peptides or purothionin) or an antibiotic (polymyxin B). 
Weanling Sprague-Dawley rats (35 ±4 g) were individually penned and self-fed the basal 
diet for a minimum of a 6-day adjustment period and then their respective experimental diets 
for 3 days. Each rat was then killed and digesta fluids from the small and large intestine 
were collected. The antimicrobial activity of the compounds in the digesta against antibiotic-
susceptible and -resistant strains of two Gram-negative and two Gram-positive bacteria were 
determined. Following oral ingestion, the proteins/peptides exhibited the ability to kill 
antibiotic-susceptible and -resistant strains of two Gram-negative and two Gram-positive 
bacteria. The minimum concentration (MIC) of each protein/peptide needed to kill bacteria 
was less for digesta from the small vs large intestine (P<.06), for Gram-negative vs Gram-
positive bacteria (P<. 11 ), and for antibiotic-susceptible vs -resistant strains of bacteria 
(P<. 10). The antibiotic polymyxin B also effectively killed in vivo each bacterium evaluated 
1 Department of Animal Science. 201 Kildee Hall, Iowa State University, Ames, LA 50011. 
"To whom correspondence should be addressed. 
3USDA/ARS/National Animal Disease Center, Dayton Road, Ames, IA 50010. 
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except antibiotic-resistant Staphylococcus aureus, while the control diet exhibited no 
antimicrobial activity. Polymyxin B was required (P<.08) in the lowest concentration in the 
diet to elicit bacterial killing compared to the proteins/peptides; however, neutrophil peptides 
and purothionin exhibited the broadest spectrum of antimicrobial activity and were the 
proteins/peptides required in the lowest concentration in the diet. Based on these results, 
natural proteins/peptides orally ingested by monogastric animals retain their ability to elicit 
antimicrobial activity throughout the gastrointestinal tract and are able to effectively kill both 
antibiotic-susceptible and -resistant bacteria. These natural proteins/peptides represent 
efficacious antibiotic alternatives. 
KEYWORDS: Antimicrobial, Natural proteins, Antibiotic resistant 
Introduction 
The greater concerns about antibiotic-resistant bacteria in both the animal and human 
population and desires to reduce pathogens in animal derived food products have created an 
increasing need to develop effective antibiotic alternatives (Piddock, 1996; Van Den 
Bogaard. 1997: Khachatourians, 1998). Proteins with these characteristics have been 
identified as components of milk (e.g., lactoferrin, lactoferricin, and alpha-lactalbumin), eggs 
(e.g., lysozyme), animal tissues and fluids (e.g., defensins), and plants (e.g., purothionin). 
These proteins potentially function as a natural anti-bacterial barrier for the pathogen-
susceptible neonate, embryo and animal-plant cells (Ganz et al.. 1990; Yamauchi et al., 1993, 
Porter et al., 1997; Garcia-Olmedo et al., 1998; and Pellegrini et al., 1999). 
In an initial study conducted by our group (Greiner et al., 2001), natural proteins/peptides 
were demonstrated to exhibit antimicrobial activity in vitro in acetic acid media as well as in 
digesta fluid of the pig. Based on these in vitro data, it was hypothesized that the feeding of 
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these natural proteins to monogastric animals would result in an increase in the enteric 
concentration of antimicrobial peptides (AMPs) via direct ingestion of AMPs or their 
precursors and indirect stimulation of endogenous AMP production. In addition, it was 
hypothesized that feeding the selected AMPs would reduce the population of enteric 
pathogens including antibiotic-susceptible and -resistant bacteria due to the AMPs unique 
mechanisms for killing bacteria compared with commercial antibiotics. However, the 
antimicrobial efficacy of these AMPs in vivo following oral ingestion has not been defined. 
Therefore, the objectives of this research were to evaluate the efficacy of orally ingested 
natural animal and plant proteins/peptides in monogastric animals to kill bacteria in vitro, to 
determine the efficacy of antimicrobial activity in the small and large intestine, against 
Gram-positive and Gram-negative bacteria, against antibiotic-resistant and -susceptible 
bacteria, and to determine minimum inhibitory concentrations of each peptide. 
Materials and Methods 
Experimental diets 
Rats were fed a basal, corn-soybean meal diet (free of antimicrobial agents. Table 1) 
that was fortified to meet or exceed all nutrient requirements of the animals (NRC, 1995). 
The seven dietary treatments consisted of the basal diet supplemented with no antimicrobial 
agent (control) or one of five natural proteins/peptides (lactoferrin, lactoferricin, lysozyme, 
neutrophil protein, or purothionin) or an antibiotic (polymyxin B). The test 
protein/peptide/antibiotic was included (at the expense of cornstarch) in the respective diet at 
the following concentrations: lactoferrin, 6,000 ppm; lactoferricin, 1,200 ppm; lysozyme, 
6,000 ppm: neutrophil peptides, 300 ppm; purothionin, 300 ppm; and polymyxin B, 45 ppm. 
These dietary concentrations were designed to provide equivalent estimated amounts of each 
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test compound in the digesta relative to each compound's previously determined minimum 
inhibitory concentration (MIC) for nalidixic-acid resistant Escherichia coli in acetic acid 
media (Greiner et al.. 2001: unpublished data). These MIC values (p.g/mL) were 100, 20, 
100, 5, 5, and .75 for lactoferrin. lactoferricin, lysozyme, neutrophil peptide, purothionin, and 
polymyxin B. respectively. The MIC of each compound was then adjusted for the 5-fold 
dilution of the digesta sample that occurred for MIC determination, assumed values for rate 
of digesta contents turnover (6 hr), undigestible portion of the protein/peptide/antibiotic 
(20%), gastrointestinal tract digesta volume (6% of body weight), and voluntary feed intake 
of the rats ( 10% of body weight/day) to estimate the amount of each compound to 
incorporate into the respective experimental diets (Appendix D). 
Animals 
Sprague-Dawley male rats were weaned at 21 days of age and transported to the 
Laboratory Animal Resource facility in Molecular Biology in Ames, IA. Rats were penned 
individually on wire bottom cages to reduce copropaghy and thus ingestion of any 
antimicrobial compounds excreted in the feces. Rats were placed in pre-sanitized cages in 
rooms isolated from other rats to minimize the magnitude and variation of the animals' 
pathogen exposure. The room temperature was maintained at 23 °C and a 12-hr light: 12 hr 
dark (8 p.m. to 8 a.m.) cycle was employed. Rats were allowed to consume feed and water 
ad libitum. 
To enable the antimicrobial evaluation procedures to be performed within the needed 
time constants and to facilitate the evaluation of the efficacy of the test compounds in rats at 
a similar stage of physiological development, two shipments of rats were received at a two-
week interval. From each shipment, five groups of 14 rats were created from outcome 
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groups based on body weight. Within each group, two rats were randomly assigned to each 
of seven treatments. At about two-day intervals, the groups (heaviest through the lightest 
group) were placed on an initial 6-day monitoring period (d 0 to 6) during which time each 
rat received the basal diet. Then, each rat received its randomly assigned experimental diet 
for 3 days (d 6 to 9). This procedure resulted in rats in each of 10 groups being placed on 
their experimental diets at body weights of 129 ± 19 g. Because of a limited availability of 
highly purified supplies of two peptides, only 10 and 7 rats of the intended 20 animals 
received the lactoferricin and purothionin peptides, respectively. In addition, due to the 
limited supplies, these animals were placed on their experimental diets (d 6) at a lighter body 
weight 70 ± 3 g and received the peptides only for the 12 hr period immediately preceding 
digesta sample collection. 
Body weight gain and feed intake (corrected for any feed wastage) were determined 
for d 0 to 6. d 6 to 9 and for the 12-hour period (7 p.m. to 7 a.m.) immediately prior to 
digesta sample collection. The growth data during the 6-day adjustment period were used as 
a baseline for rat performance before being placed on the experimental compound. Rat body 
weight gain and efficacy of feed utilization during the 3-day feeding period was used to 
determine if animal performance was altered by the oral ingestion of the 
protein/peptide/antibiotic. The voluntary feed intake for the 12-hour period prior to digesta 
sample collection was used to estimate the amount of each compound ingested prior to 
sampling of the digesta and for estimating the dietary MIC for each compound. 
Rats within each group were killed at 7 a.m. by decapitation, which was one hour before 
the light cycle was initiated, to allow collection of the digesta during times when the 
gastrointestinal contents would be high due to the night-time eating pattern of rats. Upon 
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decapitation, the ends of the small and large intestines were isolated, clamped, and the 
digesta fluid was then collected from each segment for determination of antimicrobial 
activity. 
Proteins/Peptides/Antibiotic 
Lactoferrin was provided by DMV International Mutationals (>95% pure, 80 kDa, Fraser, 
NY). Lactoferricin B was synthesized by Biopeptide Co., LLC (>90% pure, 3.2 kDa, San 
Diego. CA). Hen egg lysozyme (>95% pure, 15 kDa), purothionin (>99% pure, 5 kDa), and 
polymyxin B sulfate (> 6.000 USP units/mg, 1.5 kDa) were obtained from Sigma (St. Louis, 
MO). 
Neutrophil peptides were extracted from pig blood. Specifically, blood was collected 
from 110 kg BW pigs that had not received antimicrobial agents (oral or injected) for 3 
weeks prior to being killed. Pigs were electrically stunned, killed by exsanguination, and 
blood was immediately collected in EDTA (1 (ig / 10 mL of whole blood). Blood was 
transported on ice to prevent premature rupturing of the neutrophils. The blood was then 
layered in a 10 mL centrifuge tube onto polymorphonuclear (PMN) media (Robbins 
Scientific. Sunnyvale. CA) in a 1:2 ratio of blood to PMN media. The mixture was then 
centrifuged at 450-500 X g at 20° C for 30 min. The polymorphonuclear cell layer was then 
collected and subsequently processed to isolate neutrophil peptides as described by 
Eisenhauer et al. ( 1989). 
Briefly, 4.6 X 109 neutrophils (based on 15,000 leukocytes/gL pig blood with 30% of 
leukocytes as neutrophils. Swenson, 1984) were suspended into a solution containing 17 mL 
of cold 0.05 M sodium phosphate buffer (NaPB, pH 6.6), 2 nM 
phenylmethylsulfomylfluoride, 10 |iM leupeptin, 10 |iM pepstatin, 1 mM n-ethylmaleimide, 
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and 2 mM EOTA (Sigma). This solution was then sonicated twice for 20 seconds. The 
solution was then placed on ice for 30 minutes. Nine milliliters of cold 20% glacial acetic 
acid was then added to the solution. The cells were then sonicated for an additional 20 
seconds. The solution was stirred for I hour at 4° C and then centrifuged at 27,000 g for 20 
minutes. The supernatant was collected and lyophilized using a freeze drier system 
(LabConco. Kansas City. MO. model #77530-10) equipped with a stopring tray dryer (model 
#7948-00). The condenser was set at -60° C and the vacuum was run at < 1 X 10"5 Torr for a 
period of twelve hours. The lyophilized product (hypothesized to contain PR-39 (4.7 kDa), 
protegrin (2 kDa). and lysozyme; Hancock and Scott, 2000) was then ground into a fine 
powder and was incorporated into the rat diets. 
Animal digesta collection and recovery 
Digesta fluid was collected from each rat immediately after decapitation. The digesta 
fluid was collected from the entire small and large intestine of each rat by squeezing the fluid 
through the lumen and into a polypropylene tube. The digesta samples were immediately 
placed on ice to minimize any effects due to the time difference among animals that occurred 
between sample collection and centrifugation. The contents were centrifuged at 10,000 x g 
at 37° C for 20 min. The supernatant was decanted and then centrifuged again. This 
procedure was repeated one additional time. The supernatant was then placed into sterile 
polypropylene tubes and added to the 0.01% acetic acid media used in the antimicrobial 
activity assay. 
Antimicrobial activity assay 
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The antimicrobial activity of the digesta in the small and large intestine of rats feed each 
protein/peptide/antibiotic was evaluated against eight strains of bacteria using a radial 
diffusion assay (Lehrer et al.. 1991) as outlined in Greiner et al. (2001). 
The selection of the organisms used in this experiment was based on identifying 
organisms that are able to grow in aerobic conditions and are pathogenic. Two Gram-
negative bacteria (Escherichia coli and Salmonella enterica) and two Gram-positive bacteria 
(Staphylococcus aureus and Enterococcus faecalis) were used. For each of the four bacteria, 
a strain that had no known resistance to antibiotics and a strain that was resistant to at least 
one antibiotic were evaluated. Gram-negative E. coli and S. enterica strains that were 
susceptible (verified in our lab prior to the study) to nalidixic acid (£. colis, DH10B-
courtesey of Thad Stanton. NADC, Ames, IA; S. entericas serovar Typhimurium-courtesy of 
Karl Dawson. Alltech. Nicholasville, KY), as well as, resistant to nalidixic acid (E. coliR, pig 
isolate-courtesy of Karl Dawson, Alltech, Nicholasville. KY; 5. enterica R serovar 
Kendagou- courtesy of Karl Dawson, Alltech, Nicholasville, KY) were evaluated. Similarly, 
Gram-positive strains that were susceptible to an antibiotic (S. aureuss, ATCC #29213-
courtesey of Thad Stanton: E.faecaliss, ATCC #51575-ATCC, Manassu, VA) and resistant 
to 10 mg/mL of novobiocin (5. aureusR, ATCC #12692-ATCC, Manassu, VA) and 10 
mg/mL of streptomycin sulfate (E. faecalisR, ATCC #19433-ATCC< Manassu, VA) were 
evaluated. 
The two nalidixic acid-resistant organisms, E. coliR and S. enterica R, are transgenic forms 
of bacteria isolated from pigs and are non-isogenic to their nalidixic acid-susceptible 
counterparts. The nalidixic acid, novobiocin, and streptomycin sulfate were purchased from 
Sigma. 
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Prior to usage, the bacteria were stored in an -80°C freezer. To maintain nalidixic-
resistance of the E. coli and 5. enterica strains, 8 (ig of nalidixic acid / mL of TSB was added 
to the TSB culture tubes during growth, and .2 (ig of nalidixic acid / mL of agarose was 
added to each 10-mL tube of low EEO agarose used in the antimicrobial assay. For the 
novobiocin or streptomycin resistant bacteria, novobiocin or streptomycin was added at I and 
50 (Xg/mL of trypticase soy broth or low EEO agarose, to their respective resistant organisms. 
These antibiotics were included in the media to insure that only the responses of the 
antibiotic-resistant bacteria were being evaluated. 
Evaluation of the antimicrobial activity and data analysis 
A standard curve of antimicrobial activity in acetic acid media for each 
protein/peptide/antibiotic for each of the eight bacterial strains was created as outlined by 
Greiner et al. (2001 ). Specifically, four concentrations of each test compound for each 
bacterium were created via 3 serial, two-fold dilutions of the test compound in 0.01% acetic 
acid/NaPB media. The four concentrations used in establishing the standard curves for each 
compound were initially determined to result in a linear change in net zone diameter per unit 
change in the concentration of the test compound (Greiner et al., 2001 ; unpublished data). 
Each compound was analyzed in duplicate for each bacterium. From these data, the net zone 
diameter of bacterial killing was regressed against the log concentration of the test 
compound. The minimum inhibitory concentration of each protein/peptide/antibiotic was 
defined as the x-intercept of the semi-log regression. 
The concentration of each protein/peptide/antibiotic in the digesta from the small and 
large intestine from each animal was estimated based on the observed antimicrobial activity 
(net zone diameter) of each digesta sample relative to that of the standard curve for each 
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compound. Using the net zone diameter of each sample, the concentration of the test 
compound in each digesta sample was estimated based on the standard curve for the 
compound for that bacterium. The mean concentration of the test compound in digesta was 
calculated as the mean estimated concentration of the compound pooled across the eight 
bacteria strains evaluated. 
In order to establish the minimum amount of protein/peptide/antibiotic needed to elicit an 
antimicrobial response within the antimicrobial assay, the small and large intestine samples 
collected from each rat were added to 0.01% acetic acid in 2-serial two-fold dilutions to give 
a set of three dilutions (undiluted, 50% diluted, 25% diluted) per intestinal sample. 
Specifically, two dilutions of each digesta sample were created by adding 50 gL of undiluted 
sample into 50 |iL of the 0.01 % acetic acid/NaPB media followed by an additional two-fold 
dilution. Based on the linear relationship of microbial killing (net zone diameter) to the log 
concentrations of each peptide, the minimum inhibitory concentration (MIC) of each peptide 
(x intercept of the semi-log regression) was estimated for each respective bacterium. 
The minimum concentration of each compound required in the diet to achieve the desired 
digesta MICs also was determined. The dietary MICs were calculated from the ratio of each 
compound's minimum inhibitory concentration in digesta (Table 6 and 7) to the estimated 
total concentration of that compound in the animal's digesta ( Table 5). If the digesta MIC of 
a compound for a specific bacteria was 1/12 of the estimated total concentration of that 
compound present in the digesta, the dietary MIC of the compound is estimated as 1/12 of 
the concentration in the diet that the animal was fed. The mean dietary MIC values were 
based on the digesta MIC values from both the small and large intestine samples for each 
compound and bacteria. 
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Growth data were analyzed as a randomized complete block design by analysis of 
variance technique using the PROC MIXED procedure of SAS ( 1999-2000) with the error 
term of replication x treatment. Because of the limited quantities of purothionin and 
lactoferricin, the 3-day growth and feed consumption data for these two treatment groups 
could not be obtained. Rat growth and MIC data were analyzed using PROC MIXED and 
orthogonal contrasts to compare the response elicited by the control diet to that of the 
response elicited by the proteins-peptides-antibiotics were tested. In addition, MICs in 
digesta and the needed protein/peptide/antibiotic concentrations in feed data were analyzed 
using PROC MIXED and comparison statements for Gram-negative vs. -positive, antibiotic-
susceptible vs. -resistant, small vs. large intestine, and protein/peptide vs. antibiotic. Data 
were reported as raw means with standard deviations. 
Results and Discussion 
Efficacy of antimicrobial peptides in vivo 
A high proportion (70 to 100%) of the animals receiving each protein/peptide/antibiotic 
exhibited antimicrobial activity in digesta from both the small and large intestine against 
Gram-negative bacteria (both nalidixic acid-sensitive and -resistant strains. Table 3). These 
data demonstrate that the orally ingested antimicrobial peptides were able to elicit 
antimicrobial activity against Gram-negative bacteria and that the oral dosages fed resulted in 
enteric concentrations of antimicrobial peptides (from exogenous and/or endogenous 
sources) sufficient enough to kill the test bacteria. The proportion of the animals that 
exhibited antimicrobial activity against Gram-positive bacteria was generally lower (20 to 
100% of animals) with no animals who received the lysozyme or polymyxin B exhibiting 
antimicrobial activity against one of the four Gram-positive strains evaluated (Table 3). The 
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observation that orally ingested proteins/peptides elicited antimicrobial activity against 
Gram-positive bacteria in digesta is in contrast to the limited activity they express in an 
acetic acid media (Greiner et al., 2001). The significant Gram-positive activity in digesta 
indicates that the ingested peptides are modified to a form with a broader bacterial spectrum 
during the digestive process and/or induce release of endogenous peptides that possess a 
different spectrum. As expected, no antimicrobial activity was detected in the digesta 
samples of the control animals. These data indicate that amounts of endogenous peptides 
released into the lumen of the gastrointestinal tract are low (below detectable limits of the 
assay) in animals experiencing minimal pathogen exposure and not ingesting AMPs. 
Feed intake 12-hr prior to digesta sampling, as well as. the concentration of 
protein/peptide/antibiotic consumed during the twelve hours is listed on Table 4. 
Concentrations of peptide estimated to be present within the digesta fluid based on equating 
the net zone diameter created by the digesta samples to an equivalent net zone diameter and 
associated concentration of the test peptide in acetic acid media are reported in Table 5. 
Significant differences (Pc.01 ) in digesta concentrations of AMPs were observed in the 
protein/peptide fed groups compared with that of the control animals, but differences were 
not observed between the antibiotic and the proteins/peptides fed groups. The presence of 
antimicrobial activity (Table 3) and thus protein/peptide/antibiotic (Table 5) in the digesta 
from the large as well as small intestine indicates that the active portions of the 
protein/peptide were not degraded and absorbed in the small intestine. This observation is in 
agreement with that of Kuwata et al. (1998a) who detected fragments of lactoferrin 
containing an intact lactoferricin region in the feces of mice fed milk (40 mg lactoferrin/mL). 
This resistance of AMPs to degradation and enzymatic cleavage is likely due in part to the 
82 
greater stability of their peptide structure created by the multiple cysteine bonds commonly 
present in AMPs (Voet and Voet, 1995; Drescher, 1999). 
Based on the estimated concentrations of the protein/peptide/antibiotic in the digesta, the 
goal of providing dietary intakes of each test compound sufficient to create digesta 
concentrations that were equal to or in excess of the pretargeted MIC of each compound for 
E. coliR bacterium (based on in vitro determination in acetic acid media; Greiner et al., 2001) 
was achieved. However, the ratio of the estimated achieved concentration of each compound 
in the digesta relative to the pretargeted concentrations differed among test compounds. 
Specifically, the estimated concentrations of each compound in the digesta was equivalent to 
1 (100/100). 3.8 (76/20), .63 (63/100), 14 (72/5), 18 (90/5), and 108 (82A76) times the 
pretargeted concentrations for lactoferrin, lactoferricin, lysozyme, neutrophil peptides, 
purothionin, and polymyxin B, respectively. Differences in these ratios among compounds 
are due in part to differential changes in antimicrobial activity elicited by the test compounds 
in digesta versus the acetic acid media from which the standard curves were developed. For 
instance, as demonstrated by Greiner et al. (2001), the antimicrobial activity of lactoferrin, 
and to a lesser degree, lactoferricin and lysozyme, are increased in digesta relative to an 
acetic acid media; whereas, the activity of polymyxin B is reduced. Therefore, the 
concentrations of the protein/peptide/antibiotic in the digesta are likely overestimated to 
some extent, while that of polymyxin B is likely underestimated. The standard curves were 
developed in the acetic acid media to reduce assay variation that occurs with digesta fluid 
and because the response of the compounds in digesta in vitro would still not account for 
activity of endogenous peptides in digesta induced by feeding the test compounds. 
Differences in the ratios of estimated digesta concentrations to pretargeted concentrations 
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also are due in part to differences among compounds in their resistance to digestibility and 
absorption in the gastrointestinal tract (Drescher et al., 1999) and to inactivation in digesta 
due to change in pH (Greiner et al., 2001). 
Differences in the ratios of estimated digesta concentrations to pretargeted concentrations 
also are due in part to differences among compounds in their resistance to digestibility and 
absorption in the gastrointestinal tract and to inactivation in digesta. For example, the 
proportion of the protein/peptide that is resistant to digestion and absorption in monogastries 
differs among protein/peptide sources (Drescher et al., 1999). In addition, the loss of 
antimicrobial activity when the test compounds are exposed to a low pH (equivalent to that in 
the stomach) is less for lysozyme and polymyxin B compared with lactoferrin and 
lactoferricin (Greiner et al.. 2001). 
The minimum inhibitory concentrations (MIC) of each protein/peptide/antibiotic 
estimated to be needed in digesta from the small and large intestine to initiate killing of 
Gram-negative and Gram-positive bacteria are reported in Tables 6 and 7. A lower minimum 
concentration of each protein/peptide/antibiotic was estimated to be needed in the small 
intestine to kill bacteria compared with that of the large intestine (P<.06). This is likely due 
in part to a greater proportion of the protein/peptide/antibiotic not being digested or 
inactivated in the small versus large intestine (Drescher. 1999; Kuwata, 1998a). 
The minimum concentration of each peptide in the digesta needed to kill Gram-negative 
was lower (Pc. 11 ) than that needed for Gram-positive bacteria. The lower MIC of the test 
protein/peptide/antibiotic for Gram-negative bacteria is in agreement with the main mode of 
action of cationic AMPs. These AMPs are attracted to the negative charge of the lipid 
portions of the lipopolysaccharide (LPS) present in the outer membrane of the Gram-negative 
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bacteria (Epand and Vogel. 1999). in contrast, the Gram-positive bacteria do not have an 
outer membrane and therefore no LPS. In this instance, the cationic AMPs must then bind to 
a peptidoglycan. which contains teichoic acid (Epand and Vogel, 1999). Because Gram-
positive organisms do not possess a large quantity of teichoic acid, an antimicrobial peptide 
may be required at greater concentrations to bind to such an organism or may not be 
electrostatically attracted to the organism at all, rendering the AMP ineffective. 
The minimum concentrations of the protein/peptide/antibiotic in digesta needed to kill the 
Gram-negative bacterial strains were not altered by the susceptibility or resistance of the 
bacterial strains to nalidixic acid (Table 6). However, the minimum concentrations of the test 
compounds in digesta needed to kill the Gram-positive bacteria were less (Pc.09) for 
bacterial strains susceptible to the test antibiotic compared with those resistant to that 
antibiotic. This latter finding contradicts Hancock et al. ( 1997), who states that cationic 
peptides MICs against clinically antibiotic-resistant and -susceptible strains of Gram-
negative and Gram-positive bacteria of a given species do not vary greatly. Changes in 
membrane structure that can occur in bacteria which have developed resistance to an 
antibiotic (Brooks et. al, 1998) may alter the amount of an AMP needed to kill antibiotic 
resistant organisms particularly for AMPs that kill by lysing membranes via voltage-
dependent channel formation (Schroder, 1999). Because the nalidixic acid-susceptible and -
resistant strains of the Gram-negative bacteria evaluated were not isogenic organisms, the 
similarity in the minimum concentrations of the test compounds in digesta needed to kill the 
strains evaluated may reflect other factors than the equal sensitivity of antibiotic-susceptible 
and -resistant organisms per se to the test compounds. The antibiotic-resistant Gram-
positive organisms were naturally occurring mutations of S. aureus and E.faecalis, and 
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therefore, the greater concentrations estimated to be needed to kill the antibiotic-resistant 
organisms should be due in part to changes associated with their antibiotic-resistance per se. 
The MICs of lactoferrin, lactoferricin, lysozyme, neutrophil peptides, purothionin, and 
polymyxin B in digesta for Gram-negative bacteria were 52, 10, 12, 27, and 16 gg/mL, 
respectively (Table 6). Similar values for Gram-positive bacteria were 50, 36, 35, 27, 42, 
and 49 gg/mL. respectively (Table 7). The minimum concentrations of the test compounds 
needed in the digesta to initiate bacteria killing of Gram-negative or -positive bacteria did 
not differ for the proteins/peptides compared with the antibiotic (Tables 6 and 7). Among the 
proteins/peptides evaluated in the current study, the MICs of lactoferrin in digesta for Gram-
negative bacteria were 3 to 5 times higher (52 vs 10, 12, 27, and 16 gg/mL) than that for the 
other proteins/peptides. For Gram-positive bacteria, the MICs of the five proteins/peptides 
(50, 36, 35, 27. and 42 gg/mL) were more similar. 
The minimum inhibitory concentrations of the test proteins/peptides against E. coliR 
determined in digesta were lower than that previously determined in an acetic acid media 
(Greiner et al.. 2001 ) for lactoferrin (42 vs 100 gg/mL) and lactoferricin (3 vs 20 gg/mL), 
similar for lysozyme ( 19 vs 20 gg/mL), and greater for neutrophil peptides (31 vs 5 gg/mL) 
and purothionin (32 vs 5 gg/mL). The total concentrations of the test compounds estimated 
to be present in the digesta (Table 5) relative to the MICs of the protein/peptide/antibiotic 
needed in digesta to kill Gram-negative and -positive bacteria, respectively, were as follows: 
lactoferrin, 2 and 2 times; lactoferricin, 7 and 2 times; lysozyme, 5 and 2 times; neutrophil 
peptides, 4 and 3 times: purothionin, 5 and 2 times, and polymyxin B, 5 and 2 times. 
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The dietary concentrations of each protein/peptide estimated to be needed in the diet to 
achieve the MIC of that protein/peptide in the small and large intestine are shown in Tables 8 
and 9. As mentioned earlier, the estimated dietary concentrations required to achieve the 
MIC were developed from the ratio of the minimum inhibitory concentration of each 
protein/peptide/antibiotic in digesta to the total estimated amount of the respective compound 
in the digesta following oral ingestion. Overall, lower dietary concentrations of the test 
compounds were needed to kill bacteria in the small intestine compared with the large 
(Pc.05). as well as. to kill Gram-negative versus the Gram-positive (Pc.09), and to kill the 
Gram-positive, antibiotic-susceptible versus -resistant organisms (Pc. 10). Polymyxin B was 
required (Pc.08) in lowest dietary concentration to elicit antimicrobial activity compared to 
the proteins/peptides tested. This finding is supported by Piers et al. ( 1994) who 
demonstrated that cationic peptides rarely possess greater antimicrobial activity than 
conventional antibiotics in vitro. Of the tested AMPs, purothionin, neutrophil peptides, and 
lactoferricin were needed in lowest concentrations; whereas, lactoferrin and lysozyme were 
required in higher amounts, which supports previously reported MIC data that indicates that 
lactoferrin and lysozyme do not have strong antimicrobial activity in comparison to other 
antimicrobial peptides Ganz et al., 1990; Bellamy et al., 1992a; Jones et al., 1994; Dionysius 
and Milne, 1997; Hancock, 1997; Porter et al., 1997; Wong et al., 1998; Pellegrini et al., 
1999). In addition, lactoferrin and lysozyme as proteins, are more susceptible to inactivation 
due to binding to digesta contents (e.g., iron) and enzymatic degradation (Kuwata et al., 
1998b). Because the majority of the antimicrobial activity of lactoferrin is due to the 
lactoferricin fragment created via enzymatic cleavage in the digestive tract (Kuwata et al., 
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1998b), more dietary lactoferrin than lactoferricin would be expected to be required to 
achieve the same antimicrobial activity in digesta. 
Effect of antimicrobial peptides on rat performance 
Numerically, the short-term feeding of antimicrobial proteins/peptides resulted in a 
3.4 to 5.2 and 5.5 to 7.5%. respectively, increase in body weight gain and gain/feed ratios of 
rats when compared with those of the control group (Table 10). These responses are similar 
in magnitude to that observed in growing, monogastric animals experiencing low levels of 
antigen exposure when fed subtherapeutic concentrations of antibiotics. The differences 
between treatments for body weight gain and gain/feed were not statistically significant 
(P>0.10). The magnitude of the response would have been expected to be greater if the 
animals had received the protein/peptide/antibiotic for a longer time period and/or if the 
animals had experienced a greater level of antigen exposure. 
The value of utilizing AMPs is multi-fold. Cationic peptides tested at MIC levels have 
been shown to kill bacteria much more quickly than conventional antibiotics (Hancock, 
1997). In addition, select AMPs (e.g., alpha-lactalbumin) have been documented to trigger 
mucosal repair after injury, which is valuable in preventing bacterial attachment, 
proliferation, and bacterial invasion into the blood stream, by increasing IL-1, which has 
been shown to increase angiogenesis and cell growth (Podolsky, 1997; Kobayashi et al., 
1998). In addition, the administration of the AMP, magainin, created similar effects against 
polymicrobic diabetic ulcers compared to the orally administered antibiotic, ofloxacin, with 
few side effects (Hancock and Lehrer, 1998). Antimicrobial peptides also have the ability to 
act synergistically with each other. Hancock and Scott (2000) demonstrated that the use of 
rabbit defensins increased the antimicrobial actions of lysozyme on P. seruginosa. 
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One concern that arises from the feeding of the AMPs would be that of increasing 
bacterial resistance. Brucella spp. are resistant to certain peptides, such as cecropin PI, 
lactoferricin B. defensin NP-2. and bactenecin due to a modification of the core lipid A 
portion of the lipopolysaccharide (Martinez de Tejada et al.. 1995). In addition, Proteus spp. 
and Serratia spp. are resistant through the production of proteases that cleave some cationic 
peptides, while 6. cepacia has an outer membrane that does not permit AMP uptake 
(Hancock and Scott. 2000). However, Hancock ( 1997) states that most cationic peptides 
tested in their laboratory did not induce resistant mutants even after as many as 20 passages 
on an antimicrobial concentration close to the calculated MIC. 
Another concern with the use of AMPs would be the potential for the selective killing 
of more nonresistant than resistant bacteria. Although there is an increase in the level of 
AMP needed to kill the antibiotic-resistant, Gram-positive bacteria that were tested, the 
authors did not evaluate the use of multiple AMPs against these organisms, which could 
provide a synergistic-type of reaction and ultimately lower the MIC needed for the resistant 
organisms (Hancock and Scott. 2000). Due to the fact that AMPs have different modes of 
action than conventional antibiotics as discussed earlier, the use of AMPs may reduce the 
membrane stability of the resistant organism enough to allow for the antibiotic to effectively 
kill the organism, thereby reducing the formation of solely antibiotic-resistant flora. 
The main objective of this study was to provide evidence that selected antimicrobial 
proteins/peptides could elicit antimicrobial activity in the small and large intestine following 
oral ingestion and be fed at levels that would produce detectable antimicrobial activity. The 
data presented suggests that these proteins/peptides can in fact be fed at levels that can elicit 
antimicrobial activity against various types of organisms including resistant strains. 
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Implications 
These data demonstrate that natural proteins/peptides are potential efficacious antibiotic 
alternatives that can be fed to animals. The feeding of these AMPs also represent a potential 
technology for killing antibiotic resistant bacteria in animals. 
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Table 1. Composition of basal diet.3 
Ingredient % of Diet 
Corn, yellow, ground 63.10 
Soybean meal, dehulled 28.17 
L-Lysine. HCL .15 
D,L-Methionine .65 
L-Threonine .05 
Tryptosineh .04 
Soy oil 4.00 
Dicalcium phosphate .92 
Limestone .83 
Salt .25 
Trace mineral/vitamin mixL .83 
Ethoxyquin .01 
Corn starch1' 1.00 
a Diet was fed in meal form. 
b Consists of 70% L-lysine HCI, 15% tryptophan, 1.75% methionine, .5% valine, and .15% 
threonine. 
c Provided the following per kg of diet: Biotin .31 mg. Choline 2,250 mg, Folacin 1.4 mg, 
Niacin 45.5 mg. Pantothenic acid 24.3 mg, Riboflavin 10 mg, Pyroxidine 8.1 mg, Thiamin 
6.7 mg. Vitamin A 6062 [U. Vitamin D3 1526 IU, Vitamin E 73 IU, Vitamin K 1.8 mg, 
Vitamin B12 50 fig. Vitamin C 50 mg, Zn 120 mg, Cu 14 mg, Fe 140 mg, Mn 48 mg, 1.16 
mg, Se .3 mg. 
d Antimicrobial proteins/peptides incorporated into a com starch premix and added at the 
expense of corn starch. 
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Table 2. Concentration (gg/mL) of each protein/peptide/antibiotic used in the 
antimicrobial assay for determination of the standard curve. 
Protein/Peptide/Antibiotic Concentration (|igZmL) 
Lactoferrin 3000 
1500 
750 
375 
Lactoferricin 100 
50 
25 
12.5 
Lysozyme 500 
250 
125 
62.5 
Neutrophil protein 100 
50 
25 
12.5 
Purothionin 100 
50 
25 
12.5 
Polymyxin B 2400 
1200 
600 
300 
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Table 3. Proportion (%) of animals in which the minimum inhibitory concentration 
(MIC) of protein/peptide/antibiotic was achieved in gastrointestinal tract for Gram-
negative and Gram positive bacteria." 
Gram-Negative Gram-Positive 
Escherichia Salmonella Enterococcus Staphylococcus 
Antimicrobial Intestinal coli enterica faecalis aureus 
Source Site1" 
Susc Resc Susc Resc Susc Resc Sus Resc 
C o n t r o l  S  0 0  0  0  0 0  0  0  
L  0 0  0  0  0  0  0  0  
Lactoferrin S 95 85 75 73 80 55 55 70 
L 100 100 45 45 65 50 25 40 
Lactoferricin S 100 70 100 50 100 100 70 40 
L 100 100 100 20 100 100 30 40 
Lysozyme S 100 100 100 100 95 35 20 25 
L 100 100 65 100 90 35 0 20 
Neutrophil S 100 100 100 100 55 95 50 50 
peptides L 100 100 100 100 55 95 50 35 
Purothionin S 100 100 100 100 72 100 56 56 
L 100 86 100 100 56 100 43 43 
Polymyxin B S 100 50 55 100 50 35 25 0 
L 100 50 45 100 50 30 20 0 
J Twenty rats received each antimicrobial source except for the lactoferricin and purothionin. which 
were received by 10 and 7 rats, respectively. 
h Small (S) and large (L) intestine. 
c Antibiotic susceptible (Sus) organisms: E. coli (DH10B), S. enterica,serotype Typhimurium (pig 
isolate). E. faecalis ( ATCC # 51575). and S. aureus (ATCC #29213). 
Antibiotic resistant (Res) organisms: £. «(//-nalidixic acid (isolate). S. enterica serovar Kendagou-
nalidixic acid (isolate). E. /<zcc«/z.s-streptomycin resistant (ATCC #19433). S. ««reiM-novobiocin 
resistant (ATCC #12692). 
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Table 4. Twelve-hour intake of feed and test protein/peptide/antibiotic in rats. 
12-Hr Intake 
Antimicrobial Feed (g/rat)a Protein/Peptide/Antibiotic, 
Source gg/ratb 
Control 14.96 ± 1.4 0 
Lactoferrin 14.78 ± 1.5 88,680 
Lactoferricin 10.11 ± 1.2 12,132 
Lysozyme 14.58 ± 1.4 87,480 
Neutrophil peptides 14.82 ± 1.8 4.446 
Purothionin 5.89 ±0.4 1,767 
Polymyxin B 14.89 ± 1.5 670 
a Values reported as least square means ± standard deviation. 
h Protein/peptide/antibiotic added to feed to provide the following 
concentrations: 6,000 ppm lactoferrin, 1,200 ppm lactoferricin, 6,000 ppm 
lysozyme. 300 ppm neutrophil peptides, 300 ppm purothionin, and 45 ppm 
polymyxin B. Purothionin and lactoferricin were fed to rats weighing 70 ± 3 g 
versus the 129 ± 19 g rats used for the other treatments. 
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Table 5. Estimated concentration of protein/peptide/antibiotic (pg/mL) in the digesta 
from the small and large intestine of the rat.a 
Estimated Digesta Concentration of 
Antimicrobial Intestinal the Protein/Peptide/Antibiotic, fig/mLc 
Source Site1* 
Mean SD 
Control d S 0 0 
L 0 0 
Lactoferrin lU' S 110.0 14.8 
L 90.0 14.7 
Lactoferricin d c S 89.0 59.0 
L 64.0 43.5 
Lysozyme lU" S 67.0 29.1 
L 59.0 33.3 
Neutrophil peptides dx S 72.0 25.0 
L 72.0 38.2 
Purothionin d c S 100.0 72.9 
L 80.0 48.6 
Polymyxin B d'c S 95.0 66.2 
L 69.0 63.3 
3 Estimated concentration determined by placing the net zone values from each digesta sample 
of each tested protein/peptide into the regression equation developed from a standard curve to 
result in a concentration of protein/peptide required to achieve that amount of clearance. The 
mean concentration of the test compound in digesta was calculated as the mean estimated 
concentration of the compound pooled across the eight bacteria strains evaluated. 
b Small (S) and large (L) intestine. 
c Values reported as least square means ± standard deviation. The concentrations of 
protein/peptide/antibiotic in the feed were: 6,000 ppm lactoferrin, 1,200 ppm lactoferricin, 
6,000 ppm lysozyme. 300 ppm neutrophil peptides, 300 ppm purothionin, and 45 ppm 
polymyxin B. Purothionin and lactoferricin were fed to rats weighing 70 ± 3 g versus the 129 
± 19 g rats used for the other treatments. 
d Control digesta concentration versus proteins/peptides/antibiotics concentration, P< 01. 
c Polymyxin B digesta concentration versus proteins/peptides concentration, P>.5. 
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Table 6. Minimum inhibitory concentration (MIC, ng/mL) of protein/peptide/antibiotic 
needed in segments of the gastrointestinal tract to kill Gram-negative bacteria. 
Gram-Negative ' 
Escherichia coli Salmonella enterica 
Antimicrobial Intestinal ————— 
Source Site" Susb Resb Sus" Res" 
Control1 S 
L 
Lactoferrinll ' ~ S 50.3 ±31.3 39.0 ± 29.5 55.1 ± 19.0 54.3 ± 20.3 
L 59.2 ±2.1 44.8 ± 1.5 53.8 ±4.1 60.4 ±4.5 
Lactoferricin *' ' ' S 8.7 ± 24.2 1.2 ±8.1 11.2 ±35.9 20.0 ±5.5 
L 14.9± I.I 4.3 ± 2.3 19.9 ±3.1 2.2 ±1.2 
Lysozymed 1 ' S 7.7 ±21.5 16.1 ± 13.2 .3± 1.9 15.2 ± 18.9 
L 12.4 ±2.1 21.0 ± 2.1 2.0 ± 6.4 19.7 ± 3.2 
Neutrophil S 11.6 ± 7.3 26.9 ± 19.3 1.7 ±4.4 13.7 ±8.8 
peptidesll 1 s L 19.2 ± 1.3 34.7 ± 2.6 8.5 ± 2.3 22.0 ±2.3 
Purothionin S 11.3 ±5.5 28.3 ± 18.5 4.7 ± 32.7 13.9 ±9.4 
L 18.1 ± 1.8 36.2 ± 3.2 9.5 ±3.1 23.2 ±2.2 
Polymyxin B ll ' S 37.4 ± 26.3 .003 ±20.1 .003 ± 13.7 5.4 ± 13.4 
L 53.7± I.I .4 ±2.1 1.6 ± 9.1 10.2 ±2.2 
J Small (S) and large (L) intestine. 
h Antibiotic susceptible (Sus) organisms: E. coli (DHIOB), S. enterica serovar Typhimurium (pig isolate). 
Antibiotic resistant (Res) organisms: E. co/i-nalidixic acid (transgenic pig isolate). S. enterica serovar 
Kendagou-nalidixic acid (transgenic pig isolate). Data presented as means ± standard deviation. 
•" No antimicrobial activity exhibited. 
d MIC different for small versus large intestine. P<.06. 
e MIC different for Gram-negative versus Gram-positive. P<. 11. 
1 MIC different for control versus proteins/peptides/antibiotic. Pc.O I. 
s MIC different for antibiotic versus proteins/peptides, P<.2. 
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Table 7. Minimum inhibitory concentration (MIC, gg/ml) of protein/peptide/antibiotic 
needed in segments of the gastrointestinal tract to kill Gram-positive bacteria. 
Gram-Positiver 
Enterococcus faecalis Staphylococcus aureus 
Antimicrobial 
Source 
Intestinal 
Site" Sus1" Res'" Sus"* Res"* 
Control11 S _c 
L -
- - -
Lactoferrin'1 :"h S 47.8 ± 26.4 49.0 ±65.3 47.7 ±33.1 51.6 ±25.3 
L 52.6 ±2.1 52.6 ± 2.6 49.0 ±6.9 50.7 ±2.1 
Lactoferricin'1^'1 S 25.0 ±53.1 45.9 ±22.0 29.2 ±0 22.0 ± 11.1 
L 48.7 ± 9.0 57.0 ± 1.0 30.8 ± 2.2 30.4 ±3.1 
Lysozyme'1'1"1' S 39.7 ± 36.6 44.5 ±71.1 35.4 ± 34.2 38.3 ±48.8 
L 23.1 ±3.2 46.4 ± 3.4 - 26.0 ± 4.3 
Neutrophil S 27.7 ±22.1 48.4 ± 56.8 27.7 ± 2.5 30.1 ± 13.0 
peptides'1'1"11 L 27.6± I.I 35.7 ± 5.4 13.0 ±0 7.8 ±2.1 
Purothionin11 sh S 33.5 ± 28.8 57.2 ± 67.9 27.9 ±4.4 28.0 ± 13.2 
L 67.9 ± 17.6 51.2 ±22.2 13.0± 1.0 32.3 ±3.1 
Polymyxin B <l;" S 73.4 ±52.1 55.7 ±48.3 0.3 ± 11.2 -
L 81.1 ± 1.0 63.2 ± 1.1 18.6 ±5.4 
'' Small (S) and large (L) intestine. 
h Antibiotic susceptible (Sus) organisms: E. faecalis (ATCC # 51575). and 5. aureus (ATCC #29213). 
Antibiotic resistant (Res) organisms: E. /aem/is-streptomycin resistant (ATCC #19433), S. aureus-
novobiocin resistant (ATCC #12692). Data presented as means ± standard deviation. 
c No antimicrobial activity exhibited. 
u MIC different for small versus large intestine, P<.06. 
c MIC different for susceptible versus resistant, P<.09. 
1 MIC different for Grain-negative versus Gram-positive, P<. 11. 
s MIC different for control versus proteins/peptides/antibiotic, P<.()l. 
h MIC different for antibiotic versus proteins/peptides, P< 2. 
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Table 8. Dietary concentration (fig/g) of natural protein/peptide/antibiotic estimated to 
be needed to achieve minimal inhibitory concentrations (MIC) for Gram-negative 
bacteria in gastrointestinal tract of animals allowed to consume feed ad libitum. 
Gram-Negative " 
Escherichia coli Salmonella enterica 
Antimicrobial 
Source 
Intestinal 
Site" Sus" Res" Susb Res" 
Lactoferrin" S 40.552 ±61.0 31,445 ±58.6 44.422 ± 73.3 43.775 ±62.1 
L 58.331 ±71.0 44.140 ± 53.1 53.019 ±81.4 59.514 ±90.2 
Lactoferricin" S 1.186 ± 2.0 166 ± I.I 1.529 ± 1.0 2.723 ± 2.8 
L 2.781 ±4.3 8 I 5 ±  1 . 2  3.772 ± 6.4 4.170 ±8.9 
Lysozyme" S 10.059 ±69.3 21.027 ±22.9 392 ±4.4 19.846 ± 19.1 
L 18.389 ±59.3 21,137 ±45.1 2.965 ± 5.8 29.209 ± 26.4 
Neutrophil S 716 ± 3.9 1.661 ± 12.5 105 ±3.3 846 ±9.3 
peptides" L 1.186 ± 14.3 2.143 ± 18.2 525 ±7.2 1.359 ± 16.4 
Purothionin" S 200.0 ± 111.5 502.4 ± 112.4 83.5 ± 11.9 246.5 ± 18.7 
L 400.0 ± 111.7 801.2 ± 114.5 210.0 ± 151.1 513.1 ±99.4 
Polymyxin Bc S 264.3 ± 2.3 0.02 ± 1.1 0.02 ± 1.1 38.2 ± 14.9 
L 521.1 ±4.7 3.9 ± 1.4 15.4 ±4.1 99.4 ± 18.5 
a Small (S) and large (L) intestine. 
b Antibiotic susceptible (Sus) organisms: E. coli (DHIOB). S. enterica serovarTyphimurium (pig 
isolate). Antibiotic resistant (Res) organisms: E. ra/z'-nalidixic acid (transgenic pig isolate), S. enterica 
serovar Kendagou-nalidixic acid (transgenic pig isolate). Data presented as means ± standard deviation. 
c MIC different for small versus large intestine. P<.05. 
d MIC different for Gram-negative versus Gram-positive. P<.09. 
e MIC different of antibiotic versus proteins/peptides, P<.08. 
100 
Table 9. Dietary concentration (jig/g) of natural protein/peptide/antibiotic estimated to 
be needed to achieve minimal inhibitory concentrations (MIC) for Gram-positive 
bacteria in gastrointestinal tract of animals allowed to consume feed ad libitum. 
Gram-Positiver 
Enterococcus faecalis Staphylococcus aureus 
Antimicrobial Intestinal — —————— 
Source Site' Sus1" Res'" Susbe Res'" 
Lactoferrin11-- S 38.536 ±61.1 39,506 ±57.2 38.458 ±63.4 41,601 ±54.2 
L 51.830 ±66.7 51.832 ±61.3 48.282 ±81.2 49.960 ±72.1 
Lactoferricin'1 s S 3.409 ±19.0 6.259 ±20.3 3.980 ±23.6 2,999 ±18.1 
L 9.236 ± 25.4 10.810 ±27.9 5.837 ±31.2 5.761 ±39.1 
Lysozyme'1- S 51.836± 145.6 58.102±52.3 46.223 ±88.4 50.008+61.2 
L 34.253 ±476.8 68,797 ±89.4 -c 38,556 + 93.5 
Neutrophil S 1.71 I ± 112.0 2.989 ± 169.2 1.710± 111.3 1,861 ± 113.2 
peptidesdg L 1.714 ± 121.6 2.205 ± 136.4 802.8 ± 152.1 483.1 ± 157.6 
Purothionin11' S 591.6 ±24.4 1.012.3 ±214.4 493.5 ± 110.1 494.9 ±84.1 
L 1.499.7 ±61.3 1.130.9± 158.2 287.1 ±241.3 714.2± 102.0 
Polymyxin Bd S 517.9 ±21.0 393.2 ±54.7 2.1 ±4.6 
L 789.4 ± 32.4 613.7 ±61.3 180.6 ±86.9 
J Small (S) and large (L) intestine. 
h Antibiotic susceptible (Sus) organisms: E. faecalis (ATCC # 51575). and 5. aureus (ATCC 
#29213). Antibiotic resistant (Res) organisms: E./acca/ir-streptomycin resistant (ATCC #19433), 
S. «i/rt'H.v-novobiocin resistant (ATCC #l2692).Data presented as means ±standard deviation. 
c No antimicrobial activity exhibited. 
d MIC for small versus large intestine. P<.05. 
c MIC different for susceptible versus resistant. P<. 10. 
1 MIC different for Gram-negative versus Gram-positive. Pc.09. 
s MIC different for antibiotic versus proteins/peptides, P< O8. 
Table 10. Three-day growth and feed utilization of rats self-fed diets containing either antimicrobial 
protein/peptide/antibiotic". 
Natural Proteins/Peptides 
Criteria Control Lactoferrin Lysozyme Neutrophil Peptides 
Antibiotic 
Polymyxin B Probb 
Rat Body Weight, g 
DayO 129 ±19 128 ± 19 129 ±19 
Growth and Feed Utilization 
Daily gain, g 6.86 ±1.2 7.14 ± 1.5 7.15 ±1.0 
Daily feed, g 15.00 ± 1.4 14.78 ± 1.5 14.58 ± 1.4 
Gain/Feed .454 ±. 1 .479 ±. 1 .488 ±. 1 
129 ± 19 
7.10 ± 1.3 
14.82 ± 1.8 
.482 ±.1 
129 ± 19 
7.22 ± 1.3 
14.89 ± 1.5 
.480 ±.1 
1.0 
.16 
.21 
.15 
a Mean value ± standard deviation (SD) reported. Twenty individually-fed rats received each 
protein/peptides or antibiotic diet and eighteen rats received the control diet. 
b P-value reported as a comparison of the control (no antibiotic or antimicrobial protein/peptide) to 
the tested proteins/peptides/antibiotic. 
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CHAPTERS. GENERAL SUMMARY 
The overall objective of the dissertation research was to determine if naturally occurring 
proteins/peptides. following oral ingestion, can elicit antimicrobial activity in a monogastric 
animal. This research was performed in hopes of identifying antibiotic alternatives that 
could effectively kill antibiotic-resistant as well as susceptible bacteria in the enteric system 
of animals. 
The objectives of the first study were to validate the sensitivity and precision of an in 
vitro assay for evaluating the antimicrobial efficacy of potential antimicrobials, to evaluate 
the efficacy of natural animal proteins/peptides to kill in vitro antibiotic-resistant and -
susceptible bacteria, and to determine the effects of key components of animal digesta (e.g., 
pH and cations) on the antimicrobial activity of these proteins/peptides. 
A radial diffusion assay using a lawn of a known bacterium grown in low 
eiectroendosmosis agar with the tested peptide placed into wells within the agar was utilized. 
By regressing known concentrations of various antimicrobial protein/peptide and the 
antibiotic, polymyxin B, against the diameter of their respective clearance zones, an equation 
was developed to determine the minimum concentration of the tested peptides needed to 
produce bacterial clearance. The minimum inhibitory concentrations (MIC) for polymyxin B 
(control antibiotic) were determined to be 0.76,0.76, and 0.90 |ig/mL for Escherichia coli, 
Escherichia coli (nalidixic acid-resistant), and Staphylococcus aureus, respectively. The 
intra- and inter-assay variation for MIC determination was 0.18 Hg/mL and 0.2 gg/mL, 
respectively. Each of the natural animal proteins and peptides (lactoferrin, lactoferricin B, 
hen egg lysozyme, and alpha-lactalbumin LDT2) were verified in vitro (acetic acid medium) 
to kill nalidixic acid-resistant E. coli (£. coli - NalR). However, the required concentrations 
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of the proteins/peptides to kill E. coli - NalR were 10 to 15 times higher than needed for the 
non-isogenic, nalidixic-acid-susceptible strain. The proteins/peptides, with the exception of 
lactoferricin. did not kill Staphylococcus aureus. The antimicrobial activity of each 
protein/peptide in animal digesta fluid was 130 to 300% greater than that in the acetic acid 
media. The antimicrobial activity of lactoferrin was decreased (P<.07) in the presence of 
zinc, iron, magnesium, calcium, sodium, or potassium compared to the unexposed control. 
The antimicrobial activity of lysozyme was increased (P<.09) in the presence of zinc, 
magnesium, or calcium. The change in digesta pH from 6.5 to 2.4 resulted in a loss of 
antimicrobial activity of 65% for lactoferrin, lactoferricin, and lysozyme. Therefore, the 
enhanced antimicrobial activity of the proteins/peptides in the presence of the digesta fluid 
versus acetic acid seems not to be due to the difference in pH or mineral concentration of the 
digesta. Based on these data, natural proteins/peptides represent potential antibiotic 
alternatives for monogastric animals. 
The objective of the second study was to evaluate the efficacy of natural 
proteins/peptides to kill in vivo enteric bacteria, including antibiotic-susceptible as well as -
resistant strains. The seven dietary treatments consisted of a basal diet supplemented with no 
antimicrobial agent (control), or one of five natural proteins/peptides (lactoferrin, 
lactoferricin, lysozyme, neutrophil peptides or purothionin) or an antibiotic (polymyxin B). 
Weanling Sprague-Dawley rats (35 ± 4 g) were individually penned and self-fed the basal 
diet for a minimum of a 6-day adjustment period and then their respective experimental diets 
for 3 days. Each rat was then killed and digesta fluids from the small and large intestine 
were collected. Following oral ingestion, the proteins/peptides exhibited the ability to kill 
antibiotic-susceptible and -resistant strains of two Gram-negative and two Gram-positive 
bacteria. The minimum concentration (MIC) of each protein/peptide needed to kill bacteria 
xvas less for digesta from the small vs large intestine (Pc.06), for Gram-negative vs Gram-
positive bacteria (Pc. 11 ), and for antibiotic-susceptible vs -resistant strains of bacteira 
(Pc. 10). The antibiotic polymyxin B also effectively killed in vivo each bacterium evaluated 
except antibiotic-resistant Staphylococcus aureus, while the control diet exhibited no 
antimicrobial activity. Polymyxin B was required (Pc.08) in the lowest concentration in the 
diet to elicit bacterial killing compared to the proteins/peptides; however, neutrophil peptides 
and purothionin exhibited the broadest spectrum of antimicrobial activity and were the 
proteins/peptides required in the lowest concentration in the diet. Based on these results, 
natural proteins/peptides orally ingested by monogastric animals retain their ability to elicit 
antimicrobial activity throughout the gastrointestinal tract and are able to effectively kill both 
antibiotic-susceptible and -resistant bacteria. These natural proteins/peptides represent 
efficacious antibiotic alternatives. 
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APPENDIX A 
Recommendations for antimicrobial assay 
• Polypropylene tubes should be used to prevent peptides from binding. 
• All media should be autoclaved before use. 
• 0.01 % acetic acid media should be used. 
1. cationic peptides dissolve better in mildly acidic solutions 
2. some AMPs contain intramolecular disulfide bonds which are more stable in acid 
3. minimizes the formation of dimers and oligomers 
• Low EEO agar should be used. Other agars contain sulfated polysaccharides that will 
bind cationic peptides and prevent diffusion. 
• Any control antibiotic should be not be bacteriostatic. It should be bactericidal. 
• When pipetting samples, flush pipette tip three times before filling to desired volume to 
insure exact concentration being dispensed. 
• Gently shake the low EEO agar after the bacteria is added to provide proper mixing of the 
bacteria. 
• When punching holes in agar, dip the punch in ethanol and flame between wells to 
prevent surface contamination. 
• If small amount of bacteria are in the agar after 16 hours: 
1. The agar may have been too hot when the bacteria were added 
2. The bacteria may have been old and not in the mid-log growth phase 
3. The bacteria may not have been evenly dispersed into the agar 
4. The concentration of bacteria may have been too low 
• Freeze peptides in 0.01 % acetic acid to reduce aggregation, disulfide bond breakage, and 
adsorption to tubes 
1. CAUTION - some peptides (e.g., lysozyme) do not retain antimicrobial activity 
after multiple thawings 
APPENDIX B 
Effective peptide levels for killing bacteria. Minimum inhibitory concentrations per mL of fluid determined in vitro for 
selected antimicrobial peptides against Gram-positive and Gram-negative bacteria." 
Bacteria 
a-
lactalbumin 
peptides 
Lactoferrin Lactoferricin Defensins Lysozyme 
Gram-positive 
Bacillus cereus >9 ug 200 ug 
Bacillus circulons .3 - .6 ug 200 ug 
Bacillus natto 1 - 2 ug 200 ug 
Bacillus subtilis 1 - 25 ug . 6 -2  ug  10 - 100 ug 200 ug 
Campylobacter jejuni 12 - 18 ug NEb 
Clostridium botulinum 3.9 - 250 ug 
Clostridium pataputrificum 1 - 3 ug 
Corynebacterium ammoniagenes > 3 ug 
Corynebacterium diphtheriae 6 - 18 ug 
Corynebacterium renale .6 - 1 ug 
Enterococcus faecalis 30 -  150  ug  10 - 100 ug 
Lactobacillus casei 1 - 12 ug 10 - 100 ug 200 ug 
Listeria monocytogenes . 3 -3  ug  10 - 100 ug 200 ug 
Micrococcus luteus 1 - 25 ug 4 - 250 ug 
Staphylococcus aureus 1 - 25 ug NE 3 - 18 ug 10 - 100 ug NE 
Staphylococcus epidermidis 1 - 25 ug 3 - 6 ug 
Staphylococcus haemolyticus .6 - 1 ug 
Staphylococcus liotninus 2 -3  ug  
Staphylococcus lentus 1  - 25  ug  
Staphylococcus zooepidemica 1 - 25 ug 
Streptococcus bovis 2 - 6 ug 
Streptococcus cremoris 2 -6ug  
Streptococcus lactis 2 - 6 ug 
Gram-positive 
Streptococcus nuitans 2 - 6 ug 
Streptococcus thermoph il us 2 - 6 ug 
Gram-negative 
Acinetobacter calcoaceticus 10 - 100 ug 
Actinobacillus spp. 10 - 100 ug 
Bordetella bronchiseplica NE 
Capnocytophaga spp. 10 - 100 ug 
Escherichia coli NE >3 mg 8 - 500 ug 10 -  100  ug  >200 ug 
Haemophilus influenzae 10 - 100 ug 
Helicobacter pylori > 5 mg >2 mg 
Klebsiella pneumoniae 1 - 25 ug 9 - 12 ug 
Pasteurella 4 - 250 ug 
Pseudomonas aeruginosa NE 12 -45  ug  4 - 250 ug 
Pseudomonas cepacia NE 
Pseudomonas fluorescens NE 
Proteus vulgaris 12 -45  ug  
Salmonella enteridis 12 - 18 ug 
Salmonella montevideo <3 mg 
Salmonella typhimurium >3 mg 7.8- 15.6 ug 10 - 100 ug NE 
Serratia marcescens NE NE 10 - 100 ug 
Yersinia enterocolitica 6 -24  ug  
Yeast 
Candida albicans 7.8 - 15.6 ug 10 -  100  ug  >200 ug 
a Data represents the concentrations of the antimicrobial protein/peptide that have been reported to kill specific Gram-positive and Gram-
negative bacteria. Data summarized from the following publications, Bellamy et al., 1992; Dial et al., 1998; Dionysius and Milne, 1997; 
Ganz et al., 1990; Hancock, 1997; Hughey and Johnson, 1987; Jones et al., 1994; Kalfa and Brogden, 1999; Pellegrini et al., 1999; Porter et 
al., 1997; Tomita et al., 1998; Yamauchi et al., 1993. 
b No effect (NE) on the organism reported. 
APPENDIX C 
Semi-logarithm regression graph for minimum inhibitor) concentration determination for lactoferrin 
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APPENDIX D 
Example equation for determination of peptide concentration to be fed to rats. 
For example, it was assumed that the gastrointestinal contents represented 6% of the rat's 
body weight (Laboratory Animal NRC, 1995). The 6% was multiplied by the rat's weight 
(e.g. 130 g). This value for digesta contents (7.8 g) was then multiplied by the previously 
determined MICs of each protein/peptide in an acetic acid media (i.e., 100 pg of 
lactoferrin/mL) to obtain a value of 780 ug. It was then assumed that the rat had a 6-hour 
digesta passage rate, which meant that within 24 hours, the feed components ingested would 
turnover four times (780 * 4 = 3.12 mg of lactoferrin). It was also assumed that only 20% of 
the antimicrobial proteins/peptides would be undigested (3.12 mg X 5 = 15.6 mg) and thus 
potentially able to exhibit antimicrobial activity through the gastrointestinal tract (Drescher et 
al., 1999). Finally, this amount was adjusted by a factor of 5 to allow for the five-fold 
dilution procedure needed to estimate the MIC value (15.6 mg * 5 = 78 mg) for each peptide. 
Total feed intake was estimated to be 10% of the rat's body weight at the initiation of feeding 
the experimental diets (130 * 10% = 13 g of feed, thereby resulting in the feeding of 78 mg 
of lactoferrin in 13 g of feed per rat. 
Similar calculations were used to determine the dietary concentration of each 
protein/peptide fed. It is important to note that dietary concentrations for purothionin and 
lactoferricin were calculated using a 70 g rat with an estimated feed intake of 7 g of feed. 
The MIC values in acetic acid were used in this equation to determine dietary levels of 
lactoferrin, lactoferricin, lysozyme, neutrophil peptide, purothionin, and polymyxin B were 
100 |ig, 20 ug, 100 ug, 5ng, 5 pg, and .75 ng/mL, respectively. 
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